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INTRODUCTION 
 
 Human Immunodeficiency Virus is essentially an infection affecting the 
immune system. The main clinical manifestation is due to progressive and 
profound defect in cell mediated immunity leading to infection by variety of 
normally innocuous agents which become the major source of morbidity and 
mortality(1). HIV presently accounts for the highest number of deaths caused by 
any single infectious agent. The threat to their life being not from virus alone but 
due to opportunistic infections (OIs) and associated complications(2).  
 
 According to the UNAIDS, approximately 36.7million people were living 
with HIV/AIDS (PLHA) in 2016 globally with adult population being affected 
predominantly accounting to  approximately 34.5million(94%) and 1million death 
attributed to AIDS related illness. UNAIDS 2016 statistics of India revealed 
2.1million people were living with HIV with adult population accounting to 
2million (95%) and 62,000 death due to AIDS related illness(3,4) .  
 
 The hallmark of HIV disease is a profound immunodeficiency resulting 
primarily from a progressive quantitative and qualitative deficiency of the subset 
of T Iymphocytes referred to as helper T cells(CD4)(5). Patients with CD4+ T cell 
levels below certain thresholds are at high risk of developing a variety of 
opportunistic diseases particularly the infections and neoplasms that are       
AIDS-defining illnesses.  
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 The organisms causing OIs are usually responsible for asymptomatic or 
mildly symptomatic, self-limiting infections in immunocompetent individuals 
whereas in HIV infected patients, these infections may be severe or even life 
threatening. 
 
 Opportunistic infections had been the major cause of death in people living 
with AIDS. Since the advent of HAART, the incidence of OIs has markedly 
reduced thereby increasing the survival(6). Nevertheless significant AIDS 
associated OIs still persists because of variability in accessing ART owing to:-  
 
 (i) Unawareness of HIV infection, hence present with OI as initial indicator 
of the disease. The first clue towards the HIV pandemic were 5 homosexual males 
who presented with opportunistic infection without any previously known 
immunodeficiency in USA(1,7). Even in recent days, patients present directly with 
opportunistic infection which is the only clue towards the diagnosis of HIV  
infection.  
 (ii) Some patients though aware of their HIV status, do not take ART due 
to psychosocial or economic factors and (iii) some patients enrolled for ART, do 
not attain adequate virologic and immunologic response due to inconsistent 
retention in care, poor adherence, unfavourable pharmacokinetics or unexplained 
biologic factors(6). Hence the knowledge about the opportunistic infection 
prevalent in a region among HIV infected individuals is essential to aid in the 
diagnosis and treatment of HIV. 
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 The incidence of OIs depends on the level of immunosuppression and on 
the endemicity of the pathogen(2). Once the CD4 count falls below 200cell/µl, the 
cumulative risk of developing OIs is 33% by 1 year and 58% by 2 years. Thus the 
CD4 count serves as the crucial parameter for monitoring people living with 
HIV/AIDS as it predicts the incidence of OIs and mortality(8). In view of the same, 
initiation of primary prophylaxis for opportunistic infections is based chiefly on 
CD4 count(<200cells/µl)(9). Cure for HIV/AIDS may not be achieved but most of 
the opportunistic infections can be prevented or effectively treated, which will not 
only prolong the life expectancy of an HIV infected individual but also decrease 
the morbidity.  
 
 The various opportunistic infections seen in HIV infected patients include 
Mycobacterium tuberculosis infection, Disseminated Mycobacterium avium 
complex, recurrent bacterial pneumonia, mucocutaneous candidiasis, 
Cryptococcosis, Pneumocystis jirovecii pneumonia(PCP), Histoplamosis, 
Coccidioidomycosis, Penicilliosis, Toxoplasma gondii encephalitis, 
Cryptosporidiosis, Microsporidiosis, Varicella-zoster virus infection, Human 
Papilloma virus infection etc.  Tuberculosis is the most common opportunistic 
infection prevalent in India followed by Candidiasis, Cryptosporidiasis, Herpes 
Zoster, Pneumocytitis jirovecii pneumonia, Bacterial pneumonia and 
Cryptococcal meningitis(6).   
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 The treating physician must have a knowledge about the prevalent OIs in 
that geographical region, their diagnosis, prevention and treatment to provide 
comprehensive, quality care to the patients. The profile of pathogens responsible 
for OIs varies from country to country and even from region to region within the 
same country and with the level of immunosuppression(10). Considering this fact, 
this study was conducted to determine the prevalence of bacterial, fungal and 
parasitic opportunistic infections in HIV seropositive patients and its correlation 
with the CD4 count levels. Hence, the common pathogens causing OIs in PLHA 
with special reference to those included in the list of AIDS defining illness as per 
the CDC criteria was investigated and correlated with CD4 count.  
 
  
Aims and objectives 
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AIMS & OBJECTIVES 
 
AIM: 
 To study the prevalence of bacterial, fungal and parasitic opportunistic 
infection in People living with HIV/AIDS (PLHA). 
 
OBJECTIVES 
 To  determine the prevalence and the profile of bacterial , fungal and 
parasitic opportunistic infections in People living with HIV/AIDS by 
processing the various clinical specimens with standard microbiological 
methods. 
 To determine the Antimicrobial susceptibility pattern of the bacterial and 
fungal isolates obtained.  
 To correlate the CD4 count with the spectrum of opportunistic infections. 
 
 
 
  
Review of literature 
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REVIEW OF LITERATURE 
 
HISTORICAL REVIEW: 
 The initial clue towards HIV epidemic was in June 1981, when five 
homosexual men presented with Pneumocystis jirovecii pneumonia in the absence 
of any previously known immunosuppression were described by the Centers for 
Disease Control and Prevention(CDC) in Morbidity and Mortality Weekly 
Report(1,7). Since the epidemic was first recognized among homosexual men, the 
acronym GRID (Gay-related immune deficiency) was proposed initially. Later it 
was found that the disease affects intravenous drug users and blood transfusion 
recipients, hence the term AIDS(Acquired Immunodeficiency Syndrome) was 
adopted. In 1983, Montagnier from France and Gallo from USA individually 
isolated the retrovirus responsible for the illness and named it Lymphadenopathy-
associated virus(LAV) and Human T-cell leukemia virus type III (HTLV-III) 
respectively(1) . Subsequently, the International Committee for the Taxonomy of 
Viruses placed it in the family Retrovirus, Genus Lentivirus and was named the 
Human Immunodeficiency Virus(HIV). By April 1985, a test to detect antibody 
from blood was licensed. In 1986, HIV-2 which was related but immunologically 
distinct human retrovirus was found. Zidovudine was first used for AIDS patients 
in the year 1987. In December 1, 1988  the First World AIDS day was held. 
HAART regime was instituted from the year 1995(1).  
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 In 1989, the Guidelines for the Prophylaxis against PCP for HIV-infected 
patients became the first HIV-related treatment guideline published by U.S Public 
Health Service. Later in 1995, the guidelines was expanded to include the 
prophylaxis for all the HIV-related opportunistic infections and Infectious Disease 
Society of America joined as co-sponsor(6).  
 
 In 1986, Dr. Suniti Solomon diagnosed the first patient infected with HIV 
in India at the Govt. General Hospital(now RGGGH), Chennai among female sex 
workers from Mumbai. In 1987, the Government of India  established the 
National AIDS Control Program to restrain the spread of HIV and promote 
national efforts against HIV/AIDS.  Government of India started the free 
Antiretroviral Therapy(ART) programme on April 1st 2004(11). 
 
 In 2007 at Berlin, Stem Cell transplant for a HIV positive patient was done 
as a treatment for Leukemia from a donor missing one of HIV’s key co-receptor 
CCR5 and tested negative for HIV thereafter. This has led the researchers in 
finding a complete cure to HIV though not successful so far(12).  
 
EPIDEMIOLOGY: 
HIV Epidemiology: According to the UNAIDS, approximately 36.7million 
people were living with HIV/AIDS(PLHA) in 2016 globally with adult population 
being affected predominantly accounting to  approximately 34.5million(94%) and 
1million death attributed to AIDS related illness. UNAIDS 2016 statistics of India 
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revealed 2.1million people were living with HIV with adult population accounting 
to 2 million (95%) and 62,000 death due to AIDS related illness(3,4) . 
 
Epidemiology of Opportunistic infections(6) 
Tuberculosis 
 The estimated annual risk of reactivation with TB disease among those 
with untreated HIV infection and Latent Tuberculosis Infection (LTBI) is 3% to 
16%. In recent years there have been fewer than 1000 new cases of HIV/TB co-
infection identified per year in the United States. 
 
Disseminated Mycobacterium avium complex disease 
 M. avium is the etiologic agent in >95% of patients with AIDS who acquire 
disseminated MAC disease. An estimated 7% to 12% of adults have been 
previously infected with MAC, although rates of disease vary in different 
geographic locations. 
 
Bacterial pneumonia 
 According to the UNAIDS report, the estimated rate of pneumococcal 
pneumonia in patients with AIDS (1,094 cases per 100,000) was 55 times higher 
than in HIV-uninfected individuals (20 cases per 100,000). 
 
Mucocutaneous candidiasis 
 Oropharyngeal and esophageal candidiasis are common in HIV-infected 
patients.  Most such infections are caused by Candida albicans.  
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Pneumocystis jirovecii pneumonia 
 Before the widespread use of PCP prophylaxis and antiretroviral therapy 
(ART), PCP occurred in 70% to 80% of patients with AIDS; the course of treated 
PCP was associated with a 20% to 40% mortality rate in individuals with 
profound immunosuppression. Approximately 90% of PCP cases occurred in 
patients with CD4 T-lymphocyte (CD4 cell) counts <200 cells/mm3. 
 
Cryptosporidiosis 
 Cryptosporidiosis remains a common cause of chronic diarrhea in AIDS 
patients in developing countries, with up to 74% of diarrheal stools demonstrating 
the organism. In developed countries, cryptosporidiosis has decreased and occurs 
at an incidence of <1 case per 1000 person-years in patients with AIDS. 
 
Herpes Zoster infections 
 The incidence of herpes zoster is >15-fold higher for HIV-infected adults 
than for age-matched controls. Herpes zoster can occur in HIV-infected adults at 
any CD4 T lymphocyte (CD4) cell count, but frequency of disease is highest with 
CD4 counts of <200 cells/μL. 
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Figure 1: Opportunistic infections among patients with AIDS in India(2). 
 
 
MOLECULAR EPIDEMIOLOGY:  
There are two main types of HIV causing disease in humans: HIV-1 and HIV-2 
 
 HIV-1 has four phylogenetically distinct groups, termed group M(main), 
group O(outlier) and group N(non-M, non-O) and group P. Group M, O and N 
evolved from Chimpanzee simian immunodeficiency virus(SIVcpz) whereas 
group P from gorilla SIV (SIV gor). 95% of HIV infection globally is caused by 
Group M viruses(12). Group O infection is common occurring primarily in Central 
Africa(predominantly in cameroon) while group N is rare and limited to 
Cameroon. HIV-1  show extreme genetic diversity with atleast nine distinct 
subtypes (or clades) of Group M having 17-35% genetic sequence is seen. 
Subtype C is found predominantly in Southern Africa, Ethiopia and India and is 
responsible for nearly half of HIV infection globally. Subtype A causes 12% HIV 
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infection globally and has wide geographic distribution while subtype B 
predominates in America, Western and eastern Europe and Australia(13).  
 
 HIV-2 is a distinct retrovirus closely related to HIV-1 and is said to have 
evolved from sooty mangabey SIV(SIV smm). Though reported worldwide, it is 
more prevalent in Africa. Patients with HIV-2 infection show lower viral loads, 
reduced rate of transmission and slower progression to immunodefiency 
compared to patient with HIV-1 infection(14).  
 
MORPHOLOGY OF HIV(1,13):  
The Human Immunodeficiency Virus which causes Acquired 
Immunodeficiency Syndrome(AIDS) belong to the Family Retroviridae and 
Genus Lentivirus. 
 
 On Electron Microscopy, the virus appears spherical with an outer lipid 
bilayer(envelope) and a nucleocapsid with a dense, cone shaped core. 
 
 The lipid bilayer is derived from the host cell membrane during budding of 
the mature infectious virus particle. The outer membrane of the envelope consists 
of 72 spiked knobs assembled as trimers of the envelope protein gp120 bound to 
the transmembrane protein gp41. The membrane is rich in Cholesterol and several 
host proteins, most significantly MHC class II proteins 
 
 The nucleocapsid is icosahedral in symmetry with a cone shaped core 
which is broad at one end and narrow at the other. Each mature virion consists of 
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two molecules of single stranded RNA surrounded by three proteins encoded by 
gag gene namely, 
1. p17- matrix protein 
2. p24-major capsid protein 
3. p7-nucleoprotein which is bound tightly to viral RNA. 
 
 Along with the nucleic acid and gag proteins, the core contains transfer 
RNA(tRNA), viral protein R(vpr) and other enzymes like protease, reverse 
transcriptase and integrase 
 
HIV GENOME(13,15): 
 The proviral DNA is 9.7kb in length and has genes which code for 
structural and regulatory proteins.  
 
HIV genome has three structural genes (coding for the structural proteins) 
namely gag-pol-env gene from 5’ end flanked by two complete viral Long 
Terminal Repeats(LTR) containing transcriptional regulatory sequences, RNA 
processing signals, packaging sites, and the integration sites.  
 
1. gag gene- encodes for core and matrix proteins namely p17 and p24,p6, p7 
respectively 
2. pol gene- encodes for viral Protease(p10), Reverse Transcriptase(p66,p51) 
and Integrase (p32) 
3. env gene- encodes for outer and inner transmembrane protein gp120 and 
gp41 respectively  
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There are 6 non-structural or regulatory genes (coding for the accessory proteins 
or the regulatory proteins) arranged in a complex series of open reading frames 
1. vif (Viral Infectivity factor gene)- influences the infectivity of the viral 
particles by efficient cell-free transmission. 
2. vpr (Viral protein R)- enhances viral replication, G2 /M phase arrest. 
3. tat (Trans-activator of transcription)- major viral trans-activator, causes 
immune suppression. 
4. rev (Regulator of expression of virion protein)- enhances RNAs expression 
5. vpu (Viral protein U)- Present only in HIV-1, enhances virion release and 
reduces expression of  CD4 and MHC class I on the cell surface. 
6. nef (Negative regulatory factor)- regulates viral replication based on strain 
and cell type, reduces CD4 and MHC class I expression. 
7. Vpx (Virion protein X)- Present only in HIV-2, packaged into the virion. 
 
REPLICATION CYCLE OF HIV(13,1): 
 Steps in viral replication include attachment, penetration, uncoating, DNA 
synthesis, nuclear transport, integration, particle assembly and budding. 
 
1. ATTACHMENT:  
 Replication cycle begins with the binding of V1 region of gp120 protein on 
the viral envelope with high affinity to the CD4 molecules expressed 
predominantly on T-helper cells but also on the surface of monocytes, 
macrophages, dendritic cells and Langerhans cells. After binding to the CD4 
molecule, the gp120 protein undergoes conformational changes which facilitate it 
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to bind to either of the co-receptors CCR5 or CXCR4 expressed on the host cell.  
These co-receptors belong to the family of seven-transmembrane-domain G 
protein-coupled cellular receptors which determine the cellular tropism of the 
virus.   
 
2. PENETRATION/FUSION: 
 Due to the conformational changes occurring in gp120 protein during 
attachment, the now exposed gp41molecule penetrates the target cell plasma 
membrane bringing the virion and target cell at close proximity resulting in 
fusion.  
 
3. UNCOATING: 
 Phosphorylation of viral matrix protein by MAP kinase and pH changes 
regulated by the nef gene results in uncoating which results in release of viral 
RNA and viral enzymes in the host cytoplasm. 
 
4. DNA SYNTHESIS: 
 The viral Reverse transcriptase enzyme mediates the transcription of viral 
genomic RNA into DNA as the viral complex called the pre-integration complex 
consisting of gag matrix protein, accessory vpr protein and viral integrase along 
with the above traverse the cytoplasm to reach the nucleus. 
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5. NUCLEAR TRANSPORT: 
 The transport of the pre-intergration complex into the nucleus through the 
nuclear pore is an energy requiring process mediated by the Nuclear Localisation 
Signals present on viral gag, vpr and integrase protein. 
 
6. INTEGRATION: 
 The  integration of the viral dsDNA with the host cell chromosome is 
mediated by the viral enzyme Integrase and thus Provirus is formed. 
 
7. BIOSYNTHESIS: 
 Production of the viral particles depends on cellular and viral factors 
required for activation of the viral promoters. Some degree of cellular activation is 
necessary for transcription of the pro-viral DNA into genomic RNA and mRNA 
which are transported from the nucleus to cytoplasm where the latter translates to 
form various viral proteins. 
 
9. PARTICLE ASSEMBLY AND BUDDING: 
 Viral proteins are assembled from outermost to innermost p17, p24, 
Protease, Reverse Transcriptase, Integrase. The nucleoprotein helps in 
encapsidation. Then gp160 cleaved in Endoplasmic Reticulum and Golgi 
Apparatus into gp120 and gp 41. 
 
 Budding occurs in special regions of lipid layer called lipid rafts where the 
Nucleocapsid acquires the envelope. Protease catalyses the cleavage of gag and 
pol precursors and yields mature virion. 
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MODES OF  TRANSMISSION(5,8,16):  
1. Sexual transmission (heterosexual, homosexual) 
2. Parenteral ( transfusion of infected blood and blood products, needle prick) 
3. Mother to Child transmission ( during pregnancy, delivery and breast 
feeding) 
 
Sexual transmission : 
 Most common mode of transmission worldwide. Heterosexual transmission 
is more common particularly in developing countries though high risk of 
transmission is seen in male homosexual. 75 to 80% of HIV infection in adults are 
transmitted through unprotected sexual Intercourse(17).  ( Heterosexual – 70% 
which is common in developing countries, Homosexual –5 to 10% common in 
North America, Europe, Australia). There is strong association between anal 
intercourse and HIV as there is only a thin, fragile rectal mucous membrane 
separating semen from the cells which are the targets for HIV(17). Infection with 
microorganisms like Treponema pallidum, Haemophilus ducreyi, Neisseria 
gonorrhoea, Chlamydia, HSV, Trichomonas vaginalis cause genital ulcers and 
increase the risk of transmission of HIV 
 
Parenteral transmission : 
 Blood transfusion, blood products, or transplanted tissue with HIV can 
cause infection in the recipient. It is estimated that >90% people exposed to HIV 
tainted blood products become infected. Hence screening of blood donors for HIV 
infection is mandatory.  
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 Not only intravenous puncture but also subcutaneous or intramuscular 
injections with needle infected with HIV can transmit infection in drug abusers or 
health care professionals. HIV infection can be transmitted at the rate of 63 per 
10,000 exposure in case of needle sharing during injection drug use and 23 per 
10,000 exposure in percutaneous needle stick injury. Health Care Workers 
develop HIV by percutaneous injuries or by contact of infected material with non 
intact skin or mucous membrane. The risk of transmission of HIV by 
percutaneous injuries is 0.3% and by mucocutaneous injuries is 0.09%. 
 
Perinatal transmission: 
 Few factors which increase  perinatal transmission are advanced maternal 
stage, increased viral titres, decreased vitamin A levels, chorioamnionitis, 
maternal anaemia, etc., When the maternal viral load is less than 1000 copies/ml, 
the risk of transmission to fetus is extremely unlikely but as the load increases to 
more than 1 lakh copies/ml, the rate of transmission increases to 40%.  
 
MECHANISM OF IMMUNE DYSFUNCTION(8)  
 The main mechanism of immune dysfunction in HIV infection is by 
depletion of CD4 T lymphocytes which is a consequence of furious viral 
replication rate in these cells. About 109 CD4 T lymphocytes are killed and 
replaced in an HIV infected individual. Three major mechanisms have been 
implicated in CD4 depletion by HIV: direct virus mediated cytolysis, virus 
induced apoptosis and indirect killing through immune effector mechanism.  
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IMMUNE RESPONSE(5,13,18):  
 Both Humoral and Cell mediated immunity play an important role in HIV 
infection. 
 
Humoral Immune Response : 
 Antibodies appear within 6 to 12 weeks of infection. These are the binding 
antibodies detected by ELISA & Western Blot assay. The first antibodies detected 
are those formed against gag gene proteins p17 & p24 followed by antibodies to 
env gene proteins gp160, gp120, gp41and pol proteins p31, p51 and p66. Most of 
the neutralizing antibodies are formed against the hypervariable region of gp120 
protein which is known as the V3 loop region. Antibodies which mediate 
Antibody Dependent Cell mediated Cytotoxicity and antibodies directed against 
gp41 also help infection of cells by HIV and this phenomenon is known as 
antibody enhancement. Certain antibodies kill the uninfected also along with 
infected cells and this is known as bystander killing. The infected cells are killed 
by Complement also. 
 
Cellular Immune Response : 
 This is mediated by CD4 Helper T cells and CD8 Cytotoxic T cells. 
Though CD4 cells are the targets of HIV, they undergo proliferation and secrete 
IL-2 & IFN-γ. CD8 cells produce perforins and cause destruction of HIV infected 
cells bearing class I MHC molecules.CD8 cells inhibit the replication of HIV and 
this is mediated by chemokines MIP- 1α and MIP-1β. 
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NATURAL HISTORY OF HIV INFECTION(8,14): 
 Different phases of HIV infection occurs during a period of 8 and 12 years. 
The three distinct phases in the HIV infection are 
 
1.Primary HIV infection: Also called as Acute Infection Phase. It is a transient 
condition accompanied by initial rapid plasma viremia exceeding 10,00,000 RNA 
copies/ml, massive decrease in blood and tissue CD4 especially gut and lymph 
nodes and increase in blood CD8 T-cell count. Signs and symptoms appear 2-
4weeks after exposure and generally last less than 14days. Diagnosis relies on 
positive p24 antigen or plasma viral RNA >50,000copies/ml. 
 
2.The chronic asymptomatic phase: It is a long latency phase following primary 
HIV infection, without any signs or symptoms with stable viral replication and 
CD4 count. The virus replicates in the gut and lymphoid tissues causing its 
progressive anatomic and functional deterioration which latter result in rapid 
increase in viremia and decrease in CD4 T cell count thus transforming into overt 
AIDS. 
 
3. Overt AIDS(Acquired Immune Deficiency Syndrome):End stage, which 
when untreated leads to death in 2-3years. The opportunistic infections 
significantly increases as the CD4 count declines.  
 
Pattern of Progression(5,14): The progression of the disease may vary from person 
to person and certain patient groups were identified based on pattern of disease 
progression. 
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Typical Progressors: The median time interval to development of AIDS after 
acquiring infection is 8-10years in the absence of therapy. 80-90% of HIV 
infected individuals are “typical progressors” 
 
Rapids progressors: They develop AIDS and reach end stage within 2-3years 
with plasma viral level after primary HIV infection being >105 copies/ml and 
rapidly decreasing CD4 count. About 5-10% of PLHA fit this profile(14). 
 
Long-term non progressors: A subgroup of slow progressors with documented 
HIV infection for 8-10years, not on treatment, have no signs of disease 
progression, high CD4 count constantly and viral load <5000HIV RNA copies/ml 
of plasma. About 5% of PLHA fall in this category 
 
Elite controllers: Also called as natural controllers, are a subset of LTNPs.They 
are HIV infected individuals with chronic infection, <50copies/ml(undetectable 
level) irrespective of the period with control of viremia.  
 
  
21 
 
WHO CLINICAL STAGING OF HIV IINFECTION(2): 
Clinical Stage I 
1. Asymptomatic Infection 
2. Persistent Generalised Lymphadenopathy 
 
Clinical Stage II 
1. Unintentional Weight loss < 10% of body weight 
2. Minor mucocutaneous manifestations (dermatitis, recurrent oral ulcers,  
     angular cheilitis, fungal nail infections) 
3. Herpes zoster  
4. Recurrent upper respiratory tract infections 
 
Clinical Stage III 
1. Unintentional Weight loss > 10% of body weight 
2. Chronic diarrhoea > 1 month 
3. Fever > 1 month 
4. Oral Candidiasis 
5. Oral Hairy Leucoplakia 
6. Pulmonary TB 
7. Severe bacterial infections 
8. Vulvo vaginal Candidiasis 
 
Clinical Stage IV 
1. HIV wasting syndrome 
2. Pneumocystis jirovecii pneumonia 
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3. Toxoplasmosis of brain 
4. Cryptosporidiasis with diarrhoea > 1 month 
5. Isosporiasis with diarrhoea > 1 month 
6. Cryptococcosis (extrapulmonary) 
7. Cytomegalovirus infection of an organ other than liver, spleen or lymph      
    node 
8. Herpes Simplex infection(mucocutaneous)  
9. Progressive Multifocal Leucoencephalopathy 
10. Any disseminated endemic mycosis 
11. Candidiasis of esophagus, trachea, bronchus, lung 
12. Atypical Mycobacterial infection 
13. Non typhoid Salmonella septicaemia 
14. Extrapulmonary TB 
15. Lymphoma 
16. Kaposi’s Sarcoma 
17. HIV encephalopathy 
 
AIDS DEFINING ILLNESS(2):  
 Significant weight loss (>10% of body weight) within last one 
month/cachexia (not known to be due to a condition other than HIV 
infection) 
 Chronic diarrhoea (intermittent or continuous) for >1 month or prolonged 
fever (intermittent or continuous) for >1 month 
 Tuberculosis: Extensive pulmonary, disseminated, miliary, extrapulmonary 
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 Neurological impairment preventing independent daily activities, not 
known to be due to conditions unrelated to HIV infection (e.g. trauma) 
 Candidiasis of the oesophagus (diagnosable by oral candidiasis with 
odynophagia) 
 Clinically diagnosed life-threatening or recurrent episodes of pneumonia, 
with or without aetiological confirmation 
 Kaposi sarcoma 
 Cryptococcal meningitis 
 Cerebral toxoplasmosis 
 CMV retinitis 
 Pencillium marneffei infection 
 Recurrent herpes zoster or multidermatomal herpes infection 
 Disseminated molluscum contagiosum 
 
LABORATORY DIAGNOSIS OF HIV (5, 14,19,20) : 
 By early 1985, antibody based tests were developed in USA, by 1996 p24 
antigen capture assay was developed and by 2002, nucleic acid testing was 
developed. The diagnosis of HIV depends on detection of HIV antibodies and 
direct demonstration of HIV or one of its components. Antibodies to HIV start to 
appear from 2-12 weeks of infection (30). 
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Specimen Collection & Transport  
Specimen: 
 For serological tests(antibody and antigen detection) serum/plasma/whole 
blood,  
 Whole blood collected in K2/K3 ethylene diamine tetra acetic acid(EDTA) 
is used for CD4 enumeration, 
 For DNA/RNA PCR, Dried blood spot(DBS) or whole blood with EDTA 
is used 
 
The samples must be properly labelled.  
Specimen transport: 
 3-layer system is used for transport of the specimen 
 The tube containing specimen is placed in a leak proof container(eg. Plastic 
bag with zip-lock), This container is packer inside a cardboard box with 
sufficient cotton gauze to absorb blood in case of leak. 
 
Specimen storage: 
 Sera: 2-8oC upto 1 week, -20 C for longer duration 
 EDTA-blood for CD4 enumeration: ambient temperature upto 48hours. Do 
not refrigerate 
 Plasma for HIV-1 viral Load: Plasma should be separated within 6hours of 
collecting whole blood and stored at -20 C for longer durations. 
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Objective of testing:  
 Transfusion and transplant safety 
 Diagnosis of HIV infection in both asymptomatic and symptomatic 
individuals 
 Prevention of parent to child transmission 
 For Post-Exposure Prophylaxis(PEP) 
 Epidemiological surveillance using unlinked anonymous HIV testing 
 Research  
 
DIAGNOSTIC TESTS(14) : 
Tests for Detection of Anti-HIV Antibody: 
Screening tests 
1. ELISA 
2. Rapid tests:  
Immunoconcentration/Dot Blot Assay(vertical flow). 
Immunochromatographic Assay(lateral flow), Agglutination assay, Dipstick and 
comb assay based on Enzyme Immune Assay(EIA) 
 
Supplemental tests 
1. Immunofluorescent assay 
2. Western blot 
3. Line Immuno assay 
4. Radio Immuno Precipitation Assay 
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Other tests : 
1. P24 antigen tests 
2. DNA PCR 
3. RNA PCR 
 
Alternative tests : 
1. Saliva HIV tests 
2. Urine HIV tests 
 
SCREENING TESTS(14): Based on the principle of the assay and type of antigen 
used, serological tests are classified as first to fourth generation. 
 
Table 1: Generation of Anti-HIV antibody tests 
Generation Antigen/Antibodies Comment/Characteristic 
First Antigens from HIV lysates 
Lack of sensitivity and 
specificity 
Second 
Recombinant proteins and/or 
synthetic peptides 
Improved sensitivity 
Third 
Recombinant proteins and/or 
synthetic peptides in an antigen 
sandwich configuration 
Very high sensitivity and able to 
detect IgM antibody in addition 
to IgG antibody; reduces the 
window period considerably. 
Detects HIV-1 and HIV-2 
simultaneously 
Fourth 
Detection of both HIV 
antigen(p24) and both 
antibodies, IgG and IgM 
Further reducing the window 
period 
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ELISA:  
 This is the widely used sensitive test for HIV infection because of its high 
sensitivity. The antigen is coated on microtitre wells. The test serum is added. If 
antibodies are present, it binds to the antigen. After washing, anti human 
immunoglobulin linked to a suitable enzyme is added followed by a colour 
forming substrate. If the test serum contains anti HIV antibodies, a colour is 
formed which can be detected visually. There are four generations of ELISA. 
 
1. First generation – whole viral lysate 
2. Second generation – Recombinant antigen 
3. Third generation – synthetic peptide 
4. Fourth generation – antibody + p24 antigen (HIV duo) 
 
 Using first and second generation ELISA, antibodies can be detected in 6-
12 weeks. With third generation ELISA, antibodies can be detected in 3 weeks. 
With fourth generation ELISA, since it detects p24antigen also HIV can be 
diagnosed in 2 weeks.  
 
RAPID TESTS : 
 These tests yield results within 30 minutes with sensitivity and specificity 
comparable to ELISA. The most commonly used  rapid anti-HIV tests are based 
on the principle of Immunoconcentration/Dot Blot Assay(vertical flow). 
Immunochromatographic Assay(lateral flow), Agglutination assay, Dipstick and 
comb assay based on Enzyme Immune Assay(EIA) 
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Advantages: 
 Point of care tests 
 Don’t require special equipment 
 Technically simple to perform 
 Stores in ambient temperature(20-25 C) 
 
WESTERN BLOT : 
 This assay is based on the fact that various HIV antigens of different 
molecular weight induces the production of specific antibodies. The antibodies to 
each component produces a band. So the HIV proteins are separated according to 
their molecular weight and electrophoretic mobility by polyacrylamide gel 
electrophoresis and blotted on strips of nitrocellulose paper. The strips are reacted 
with test sera and then with anti human immunoglobulin conjugated with enzyme. 
A suitable substrate is then added which produces a colour band where specific 
antibody has reacted with the separated viral antigen. The position of the band 
indicates the antigen with which the antibody has reacted. 
 
Interpretation : 
Positive Western Blot Criteria : 
1. WHO – 2 env with/without gag/pol 
2. CDC – Any two p24, gp41, gp120, gp160 
 
Negative – no bands 
 Indeterminate – bands present but does not satisfy the criteria. 
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Limitations of Antibody Assay: 
 Antibodies not detected in window period 
 Not useful in children below 18months of age 
 
P24 ANTIGEN TEST : 
 P24 antigen tests are also ELISA based and use antibodies to capture the 
disrupted antigen. This antigen becomes detectable as early as two weeks and 
lasts for 3-4 weeks and elevates again during late stage of AIDS. But it is less 
sensitive. 
 
Uses : 
1. During the window period 
2. To detect HIV infection in newborn(not reliable) 
3. During late stage of HIV/AIDS(immune collapse). 
4. Monitoring progress of HIV infection 
 
Viral RNA Detection: 
 It is the “Gold standard” method for confirmation of HIV infection. Three 
different techniques are available Reverse transcriptase Polymerase Chain 
reaction (RT-PCR), Nucleic Acid Sequence Based Amplification(NASBA), 
branched DNA Assay an Real-time RT-PCR. In this the target HIV RNA is 
amplified enzymatically invitro by chemical methods. It is extremely sensitive 
and specific detecting even few copies of viral RNA. HIV nucleic acid is 
detectable as early as 12 days hence used in diagnosing during window period. 
Can be used to monitor viral load, typing HIV and detecting drug resistance. 
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DNA PCR: 
 It detects proviral DNA. It is extremely useful in detecting paediatric HIV, 
to differentiate latent HIV infection from active viral transcription, viral load 
estimation and genotype detection.  
 
NEWER TESTS : 
ORASURE- SALIVA HIV TEST : 
 Non-invasively collected specimens like oral fluid, saliva and oral mucosal 
transudate are used. These systems detect antibodies comparable to or exceeding 
serum samples. 
 
URINE TESTS : 
 IgG antibodies are found in urine. The collection of urine is simple, 
noninvasive and so more useful in developing countries where trained technicians 
are not available for collecting blood. 
 
LAB MONITORING OF PATIENTS WITH HIV INFECTION (14): 
 The laboratory tests used for monitoring the stage and progression of HIV 
infection are 
1. Immunological tests 
 CD4 T cell enumeration 
2. Virological assays 
 HIV RNA load assay 
 Measurement of HIV p24 
 Reverse Transcriptase activity assay 
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CD4 COUNT : 
 CD4 count measures the degree of immunosuppression. CD4 progressively 
declines as the immune function decreases. It is used in staging the disease, 
monitoring disease progression, serves as a guide to start ART, determining 
treatment failure. CD4 cell count is the best predictor of disease progression and it 
is cheaper than viral load. So it is useful in developing and poor nations (21). 
 
 The WHO 2010 recommendations states that all HIV positive adults with 
CD4 count less than 350 cells/µl should be started on ART with or without 
symptoms. WHO defines immunological failure as fall of CD4 count to baseline 
or below or 50% decrease of CD4 count from on treatment peak value or 
persistent CD4 count below 100 cells/µl. 
 
The U.S. CDC uses CD4 count and divides AIDS into three categories A, 
B, C. Category A CD4 count >500 cells/µl, Category B CD4 count 200-499 
cells/µl, Category C CD4 count <200 cells/µl. According to CDC, AIDS is HIV 
infection with CD4 count < 200 cells/ml or CD4% < 14%. But WHO staging does 
not include CD4 count to accommodate poor nations (18). 
 
HIV VIRAL LOAD : 
 It is a direct measure of in vivo replication of virus and therefore it is a 
powerful prognostic tool (22). Measurement of viral load is based on getting the 
target RNA, Reverse Transcription of RNA into cDNA, PCR amplification of 
target DNA and detection of dual fluorescent labelled oligonucleotide probes 
which quantifies HIV-1 target RNA. The test can detect and quantitate HIV-1 
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RNA as few as 40-50 copies/ml of plasma. Therapy is considered in patients with 
more than 1,00,000 copies/ml. During therapy, viral load is determined every 3-4 
months. Reduction of viral load less than 50 copies/ml in 6 months indicates 
effective treatment. 
 
Uses : 
1. Guide for initiating ART 
2. Optimising the duration of treatment. 
3. Switching to second line of treatment 
 
TREATMENT(14):  
 The main aim of ART is to reduce viral load to improve the quality of life 
and increase the life span of the patients. HAART regimens helps in preventing 
opportunistic infection.  
 
Table 2: Goals of ARV therapy(14) 
 Clinical goals : Prolongation of life and improvement in quality of life  
 Virological goals : Greatest possible reduction in viral load for as long as 
possible  
 Immunological goals : Immune reconstitution that is both quantitative and 
qualitative  
 Therapeutic goals : Rational sequencing of drugs in a fashion that achieves 
clinical, virological and immunological goals while maintaining treatment 
options, limiting drug toxicity and facilitating adherence  
 Reduction of HIV transmission in individuals : Reduction of HIV 
transmission by suppression of viral load  
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Table 3: Initiation of ART, based on CD4 count and WHO clinical staging  
WHO Clinical Stage Recommendations 
HIV infected Adults & Adolescents (Including pregnant women) 
Clinical Stage I and II Start ART if CD4 < 350 cells/mm3 
Clinical Stage III and IV Start ART irrespective of CD4 count 
 
Classification of drugs : 
1. Drugs inhibiting the viral reverse transcriptase enzymes 
a. Nucleoside Reverse transcriptase inhibitors- Zidovudine, 
didanosine, Zalcitabine, Stavudine, Lamivudine, abacavir. 
b. Non –Nucleoside Reverse transcriptase inhibitors – Nevirapine, 
Delaviridine, Efavirenz. 
c. Nucleotide Reverse transcriptase inhibitors – Tenofovir. 
2. Drugs inhibiting Protease enzyme – Ritonavir, Indinavir, Saquinavir, 
Amprenavir, Lopinavir, Nelfinavir,Atazanavir, Darunavir. 
3.  Drugs inhibiting Integrase enzyme – Raltegravir 
4. Drugs inhibiting Viral entry – Maroviroc 
5. Drugs inhibiting Fusion of viral envelope with host cell- Enfuvirtide. 
 
Principles for selecting the first-line regimen  
1. Choose 3TC (Lamivudine) in all regimens  
2. Choose one NRTI to combine with 3TC (AZT or TDF)  
3. Choose one NNRTI (NVP or EFV) 
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DRUG RESISTANCE(13,23):   
 Drug resistance is common with monotherapy in HIV infected patient by 
mutation and natural selection within weeks or months(6). 
 
 Resistance to NRTIs is due to two mechanisms which prevent the 
incorporation of the triphosphorylated NRTIs. The first mechanism is a mutation 
that allows reverse transcriptase to recognise NRTIs during DNA synthesis 
thereby preventing their addition in primer DNA chain. The second mechanism is 
a mutation in the enzyme that enhance the hydrolytic removal of the chain 
terminating NRTIs, hence continue the DNA synthesis.     
 
Resistance to NNRTIs is by a single mutation in the hydrophobic pocket 
close to the active site in reverse transcriptase where the NNRTs binds. This 
binding displaces the catalytic aspartate residue relative to the polymerase binding 
site hence inhibit HIV-1 replication.  
 
The HIV exhibit resistance to Protease inhibitor is due to mutation in the 
cleavage sites, causing structural changes which reduce the binding affinity 
between the inhibitor and mutant protease molecule.  
 
In order to prevent resistant strains to evolve, combination therapy with 
two or three drugs with different mode of action is give.  
 
Drug resistance can be identified at three levels. First clinically by 
unresponsiveness with rapid fall in CD4 count and rise in plasma HIV RNA level 
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in a patient on regular treatment. Second is phenotypic method by viral isolation 
followed by drug susceptibility testing in cell culture. But it is cumbersome and 
expensive. Last is  genotypic method by using PCR to amplify and screen for viral 
geneome with common mutation patterns. 
 
HIV DRUG RESISTANCE TESTING (5,16) : 
 It measures the sensitivity of individual’s HIV to different ARV agents 
which can be measured by phenotypic and genotypic methods. In genotypic 
assays, sequence analysis of patient’s HIV is compared with sequence of virus 
with known ARV resistance profiles. In phenotypic methods the in vivo growth of 
the virus is compared with reference strains in the presence and absence of ARV 
agents. 
 
Uses : 
1. Selecting an initial regimen for treatment of new patients 
2. Selecting new drugs in drug failure 
 
OPPORTUNISTIC INFECTIONS(2,6): 
BACTERIAL OPPORTUNISTIC INFECTIONS:  
1.Tuberculosis(TB):  
 Of all the opportunistic infection, Mycobacterium tuberculosis is the most 
common serious opportunistic infection and leading cause of morbidity and 
mortality in HIV infected patients globally(2). The incidence of TB doubles in the 
first year following HIV infection and the risk increases with progressive 
immunodeficiency but can occur in any stage of HIV infection(16,24).  
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 Clinical presentation: Cough for more than 3 weeks which is not 
responding to antibiotic treatment. Purulent or blood-stained sputum. Night 
sweats, Weight loss and evening rise of temperature. 
 
 Diagnosis: Chest radiography reveals miliary pattern, hilar adenopathy, 
pleural effusion, focal infiltrates in upper and hilar regions, multilobar infiltrates, 
Interstitial infiltrates, cavitation with severe immunosuppression, X-ray might 
appear normal.  
 
Treatment:   
Table 4: Treatment Categories and Regimens for Tuberculosis(5) 
Category Type of patients 
Treatment Regimens 
Intensive 
phase 
Continuation 
phase 
Category I 
All new pulmonary(smear 
positive and negative), and 
extrapulmonary TB cases 
2 HRZE 4 HR 
Category II 
Previously treated cases; 
relapses or treatment 
defaulters 
2HRZES+ 
1HRZE 5 HRE 
H= Isoniazid, R=Rifampicin, Z=Pyrazinamide, E=Ethambutol, S=Streptomycin 
The number before the letters refers to the number of months of treatment 
 
2.Mycobacterium Avium Complex(MAC)(2): MAC can cause life-threatening 
symptoms and disseminated disease in advanced HIV disease. MAC is ubiquitous 
in nature and is found in water, soil and food. It is not seen very commonly in 
Indian patients with HIV. 
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Clinical Presentation: A clinical diagnosis is based on MAC syndrome criteria 
which consists of 1 of the following: persistent fever for more than one week, 
night sweats, diarrhoea, weight loss or wasting, hepatomegaly, splenomegaly, 
anaemia and alkaline phosphatase more than twice the upper limit of normal. 
 
Diagnosis: X-ray reveals pulmonary infiltrates. The diagnosis is confirmed if 
MAC is isolated from normally sterile body fluid or tissue and is considered 
probable if MAC is isolated from the skin surface, bronchopulmonary, 
gastrointestinal, or other non-sterile sites along with histopathological 
confirmation of AFB/MAC. 
 
Treatment: Combination therapy is generally suggested to prevent resistance. 
Clarithromycin is highly effective while Azithromycin is an excellent substitute in 
cases of drug interactions or side-effects. Lifelong maintenance therapy is 
recommmended to prevent recurrence, but may be discontinued when CD4 count 
rises to  >100 cells/µl. 
 
Prophylaxis: Prophylaxis is usually started when  CD4 count is <75 cells/µl. 
Macrolides are effective drugs with risk reduction rates of 70%. Clarithromycin 
once a day or azithromycin once a week is given as prophylaxis. However, routine 
prophylaxis for MAC is currently not recommended in India.  
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3. Bacterial pneumonias(6): Community acquired bacterial pneumonia is  three to 
fivefold more common in PLHA than among HIV negative individuals. The risk 
increases with lower CD4 count, intravenous drug use and cigarette smoking.  
 
Clinical presentation: Presents with typical symptoms of pneumonia like fever, 
productive cough, dypnea and pleuritic chest pain. Physical examination reveals 
localized pulmonary findings. 
 
Diagnosis: Chest radiography reveals focal infiltrates. Sputum culture is usually 
positive with multiple polymorphonuclear cells in direct gram stained smear. 
Leukocytosis and hypoxemia are the other findings. The most common pathogens 
associated with pneumonia in HIV-infected patients includes S.pneumoniae, 
H.influenzae, Klebsiella pneumoniae, Staphylococcus aureus and Pseudomonas 
aeruginosa.  
 
Treatment: Second or third generation cephalosporins can be given empirically 
which can later be streamlined.  
Prophylaxis: Optimizing ART is the most effective strategy to prevent 
recurrence. When the CD4 counts falls below 200 cells/µl, a single dose of 23-
valent polysaccharide pneumococcal vaccine should be administered if they have 
not received it in the preceding five years. Using antibiotics solely to prevent 
recurrence is not recommended as it may lead to the development of drug-
resistant strains and drug toxicity. 
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4.Bacteremia: Associated with Salmonella spp infections or pneumonia. The 
most common organism isolated are Staphylococcus aureus and coagulase 
negative Staphylococci although few gram negative organisms are also seen. 
Empiric therapy include Vancomycin with aminoglycosides/ -lactam antibiotics.    
 
FUNGAL OPPORTUNISTIC INFECTIONS(2,6,25): Fungi are the most 
common pathogen seen in PLHA but are not common cause of mortality.    
 
1.Candidiasis:  
It causes exclusively mucosal infection with oropharyngeal candidiasis 
seen in about 3/4th of patients with HIV infection. In one-third of the patients it 
tends to recur and progress in severity with increasing immunodeficiency. 
Esophageal candidiasis is seen in 20-40% of AIDS patients predominantly with 
very low CD4 count. Oral Candidiasis is frequently the first indication of immune 
impairment in HIV-infected patients. The most common candida species causing 
infection in AIDS patient is C.albicans though C.glabrata, C.dubliniensis, 
C.parapsilosis tend to cause infection in advanced disease.  
 
Clinical Manifestations: Patients with oral candidiasis complain of oral 
discomfort and classically present with creamy-white plaques on an erythematous 
base(pseudomembrane form of oral thrush), other manifestations include 
erythema without plaque(atrophic form) and angular cheilits. Pateints with 
esophageal candidiasis complain of odynophagia or dysphagia due to ulcers and 
erosions in the esophagus.  
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Diagnosis: Clinical Diagnosis is usually based on the characteristic appearance of 
the lesions along with the ease with which the whitish plaques can be scraped off. 
The diagnosis is by microscopic demonstration of the yeast forms from scrapings 
using a 10% potassium hydroxide (KOH) preparation and culture. The 
oesophageal candidiasis is diagnosed by endoscopic visualization of the lesions 
along with histopathological demonstration and culture confirmation. 
 
Treatment: Appearance of oral candidiasis is a sign of progressive 
immunodeficiency and the patient should have their CD4 count measured. If the 
patient is not on ART, it should be initiated and if already on ART, it should be 
reassessed. For oral candidiasis  either local or systemic therapy can be given but 
for esophageal candidiasis systemic therapy is indicated. Clotrimazole troche 10 
mg five times/day until the lesions resolve (usually 7–14 days) or Nystatin oral 
suspension 500000 units which is gargled 4–5 times/day may be used topically. 
Oral medications include fluconazole 100–200 mg/day (150 mg tab x 1–2 times 
daily) for 7–14 days(2).  
 
Prophylaxis: Recurrence is common in about one-third of the patients and most 
commonly in patients who are not on ART. But prophylaxis is not indicated. 
 
2.Cryptococcosis:  
 Occurs in patients with very low CD4 count (<50cells/µl). Virtually all 
Cryptococcosis in HIV infected patient is caused by Cryptococcus neoformans 
var neoformans.   
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Clinical manifestations: Most common presentation is subacute meningitis or 
meningoencephalitis with fever, malaise and headache for a period of 2-4weeks. 
Only one third of patients present with classical signs and symptoms of 
meningitis, while some present with symptoms of encephalopathy like lethargy, 
altered sensorium, personality changes and memory loss.  
 
Diagnosis: CSF analysis reveals mildly elevated protein, normal or slightly low 
glucose, with few lymphocytes. Elevated CSF opening pressure is seen in about 
25% of patients. Organism can be demonstrated in CSF by negative staining 
methods like India ink staining or Nigrosin staining(Capsulated round budding 
yeast cells), antigen detection by lateral flow assay or latex agglutination test and 
isolation in culture on Sabouraud Dextrose agar at 37 C. A high titre of more 
than 1:8 for serum Cryptococcal antigen is presumptive evidence of Cryptococcal 
infection. 
 
Treatment: Cryptococcal meningitis if untreated becomes fatal. Treatment 
includes Amphotericin B(0.7mg/kg) given intravenously for 2 weeks followed by 
maintenance with fluconazole 400mg orally for 8weeks. ART should be initiated 
and patient should be monitored for development of IRIS. 
 
Prophylaxis: Require long-term treatment with fluconazole 200mg daily until 
immune function improves with CD4 count >200cells/µl persistently and 
undetectable plasma HIV RNA.  
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3.Pneumocystis jirovecii Pneumonia:  
Previously known as Pneumocystis carinii. It is an opportunistic fungal 
pathogen causing especially pneumonia(PCP) in patients with impaired cell 
mediated immunity. The initial clue towards the AIDS epidemic were 5 
homosexual men who presented with PCP in the absence of previously known 
immune deficiency disorder. Though the advent of HAART has reduced its 
incidence, it still remains as an important pathogen causing OI. The risk of 
acquiring PCP infection increases when the CD4 count reduces beyond 
200cell/µl. The rate of relapse following first episode of PCP is high  which is 
approximately 60% within 1 year if no specific prophylaxis or HAART is given to 
the patient.  
 
Clinical Features: 95% restricted to lung presenting most commonly with 
progressive dyspnea with dry cough, mild fever and weight loss for 3-4 weeks. On 
examination, tachypnea is common though lung auscultation may be normal. 
Diagnosis: Chest radiography is an important step to guide towards the diagnosis 
which reveals fine bilateral interstitial and followed by alveolar-interstitial 
infiltrate progressing from perihilar to peripheral regions. In advanced cases, 
progressive consolidation with air bronchograms and complete opacification of 
the lung may be seen. Arterial blood gases must be measured to assess the 
severity of the disease. Definitive diagnosis requires morphological demonstration 
of the organism. Bronchoalveolar lavage(BAL) being the reference diagnostic 
specimen with sensitivity of 95% followed by induced sputum with sensitivity of 
50-60%(11,14). Under high suspicion yet unable to demonstrate the organism in 
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BAL, transbronchial lung biopsy may help but it has the risk of bleeding and 
pneumothorax. The various methods used to demonstrate the organism include 
Methanamine silver stain(gold standard), mucicarmine staining, Giemsa staining, 
immunofluorescence technique used with fluroscent tagged antibody against 
P.jirovecii and Polymerase chain reaction. 
 
Treatment: Severity of the disease is measured by arterial blood gas as mild 
(PaO2  70mmHg), moderate (PaO2 50-70mmHg) and severe (PaO2  <50mmHg). 
Patients with moderate and severe PCP are hospitalized and treated with 
Trimethoprim-sulfamethoxazole with 15mg/kg/day trimethoprim with 
75mg/kg/day sulfamethoxazole in three divided doses. Corticosteroids are also 
administered in patients with PaO2  <65mmHg to improve oxygenation, reduce 
risk of fibrosis and need for mechanical ventilation. Treatment should be given for 
a period of 21days.  
 
Prophylaxis: Indicated for PLHA with CD4 count <200cells/µl or with history of 
oropharyngeal candidiasis or any AIDS-defining illness(26). Trimethoprim-
sulfamethoxazole is recommended for prophylaxis per day till the CD4 count 
increases to >200cells/µl and persists for on two consecutive occasions within a 
period of 6 months(2). 
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4.Microsporidiosis: It is an intracellular organism which had undergone 
taxonomic change recently and has been re-classified from Protozoa to the 
Kingdom Fungi(25). Microsporidiosis is common in PLHA with CD4 count are 
<100cells/µl. 
 
Clinical Manifestations: The most common presentation is diarrhea, however 
encephalitis, ocular infection, sinutsitis, myositis and disseminated infection.  
 
Diagnosis: Chromotrope 2R and calcofluor white are few selective stains useful 
for identification of microsporidia in stoll and other body fluids. Tissue stains like 
Giemsa, tissue Gram stains (Brown-Hopps Gram stain) and calcofluor white are 
useful in identification in biopsy specimens(22). 
 
Treatment: Restoration of immune with ART to achieve CD4 count 
>100cells/µl, correction of dehydration, malnutrition and wasting with fluid 
support and nutritional supplements wherever applicable.  
 
Prophylaxis: Initiation and optimization of ART to restore immunity in advanced 
immunodeficiency would prevent the disease 
 
PARASITIC OPPORTUNISTIC INFECTIONS(2,6,27) 
1.Cryptosporidiosis:  
 Protozoan parasite Cryptosporidium, the causative organism infects the 
small bowel mucosa and presents with diarrhea if symptomatic. CD4 count of 
<100cells/µl. Common cause of chronic diarrhea in AIDS patients in developing 
countries with up to 74% diarrheal stool samples demonstrating the organism(28).  
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Clinical Manifestations: Most commonly presents with acute or subacute watery 
diarrhea, accompanied by nausea, vomiting and lower abdominal cramping 
Diagnosis: Microscopic identification of oocyst in stool with acid-fast staining or 
direct immunofluorescence. Immunofluorescence is 10 times more sensitive than 
acid-fast staining(29). Concentration methods, sedimentation (formalin ether) or 
floatation methods(Sheather’s) may facilitate the diagnosis. Antigen detection 
with ELISA or immunochromatography can be done. Molecular methods like 
Polymerase chain reaction (PCR) can detect as low as 5 oocyst in spiked stool 
sample. Single sample is sufficient for diagnosis in case of profuse diarrheal 
illness, whereas repeat stool sample is required for milder disease. 
 
Treatment: Restoration of immunity with CD4 cell count to >100cells/µl  with 
ART is sufficient to achieve resolution from clinical cryptosporidiosis(30). Along 
with it rehydration and correction of electrolyte imbalance is sufficient.  
 
Prophylaxis: Restoration of immunity with ART is recommended for its 
prevention. 
 
2. Isosporiasis:  
 It is caused by the protozoon Isospora belli which infects small intestine 
causing severe diarrhoea and malabsorption. It spreads by food or water 
contaminated with animal faeces. It causes prolonged, severe diarrhoea and 
malabsorption when the CD4 count falls to <150cells/µl. 
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Clinical features: Presents with watery diarrhoea, abdominal pain, flatulence, 
weight loss, loss of appetite and dehydration are the presenting features.  
 
Diagnosis: The organism is demonstrated by microscopic examination of the 
stained (Acid Fast Staining) stool sample.  
 
Treatment: Two double-strength TMP–SMX tablets 160/800mg twice daily, or 
one double-strength tablet q6h daily for 10 days followed by 3 times/day for 3 
weeks is the treatment of choice. In cases of sulfa allergy, pyrimethamine and 
folinic acid may be given for a month.  
 
3.Toxoplasma gondii Encephalitis:  
 It is caused by the protozoa Toxoplasma gondii occurring due to 
reactivation of latent tissue cyst(20). Risk of infection is high when the CD4 count 
is  <50cells/µl(21).  
 
Clinical Manifestations: Most common presentation is focal encephalitis 
presenting with headache, confusion, motor weakness and fever which may 
progress to seizures, stupor, coma and death. Physical examination reveals focal 
neurological abnormalities.  
 
Diagnosis: Computed tomography (CT) or magnetic resonance imaging(MRI) of 
brain shows typical multiple contrast-enhancing lesions in grey matter of the 
cortex or basal ganglia with edema. PLHA patients with Toxoplasmic encephalitis 
are almost uniformly seropositive for anti-toxoplasma IgG and IgM are usually 
absent(18).  
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Treatment: Pyrimethamine with sulfadiazine and leucovorin along with PCP 
prophylaxis(13).  
 
Prophylaxis: Given for patients with CD4 count <100cell/µl. Trimethoprim-
sulfamethoxazole(TMP-SMX)  double strength 3times weekly until CD4 count 
increase to >200cells/µl for more than 3months. If the patient is on PCP 
prophylaxis with TMP-SMX, no additional medication is required for 
Toxoplasma pophylaxis(13). 
 
CD4 COUNT AND OPPORTUNISTIC INFECTIONS IN HIV INFECTION: 
 The number of circulating CD4 T-lymphocytes closely correlate with the 
risk of acquiring several opportunistic infections.  
 
Figure 2: Association between opportunistic infections and  
CD4 Lymphocyte count(2) 
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IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME(IRIS)(2): 
 IRIS refers to atypical manifestations of OIs with paradoxical clinical 
deterioration following initiation of HAART. This syndrome is well-described for 
TB, Cryptococcosis and PCP. It must be distinguished from failure to treatment or 
prophylaxis, as the management is different. 
 
 IRIS is described as an adverse clinical phenomenon following rapid 
restoration of immune function in a previously severely immunocompromised 
individual. A temporal relationship with commencement of HAART and 
exclusion of an alternative explanation must be established.  
 
 PLHA recently started on HAART who develop IRD must continue on 
treatment with both ART and treatment of OI. Steroids are used in life-threatening 
conditions.  
 
PREVENTION OF OPPORTUNISTIC INFECTIONS(2):  
 Primary prophylaxis should be started in all HIV infected patients when 
they present under WHO Stage III or Stage II with CD4 count <200cells/µl. It 
may be discontinued when the CD4 cell count is >200cells/µl for 6 months.  
 
 Co-trimoxazole (Sulfamethoxazole/trimethoprim) 800mg/160mg PO once 
daily is the recommended prophylaxis. It is effective in preventing PCP, 
toxoplasmosis, certain bacterial pneumonias, Nocardiosis and enteric pathogen. In 
case of allergy to co-trimoxazole, alternative primary prophylaxis against PCP 
and toxoplasmosis is dapsone 100mg once daily with pyrimethamine 50mg 
weekly. Desensitization may be suggested for sulfa allergy.  
Materials and methods 
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MATERIALS AND METHODS 
 
STUDY DESIGN   : Cross sectional study 
STUDY PERIOD   :  1 year (July 2016-June 2017) 
 
STUDY SETTING : 
 The study was conducted in the Institute of Microbiology, in association 
with Integrated Counselling and Testing Centre, Institute of General Surgery and 
Institute of Internal Medicine,   Madras Medical College & RGGGH.  
 
ETHICAL CONSIDERATION:  
All patients satisfying the following criteria were included in the study 
after obtaining informed written consent in both regional language and English. 
This study was reviewed and approved by Institutional Ethical Committee with 
clearance number 17062016. Confidentiality and anonymity were maintained 
during the study.             
 
SAMPLE SIZE  : 140 People living with HIV/AIDS having clinical 
symptoms and signs suggestive of OI  
 
INCLUSION CRITERIA: 
• HIV positive patients more than 18 years of age 
• PLHA with clinical symptoms and signs suggestive of OIs 
 
EXCLUSION CRITERIA: 
 Patients who did not give consent  
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METHODOLOGY: 
 Confidentiality of HIV status of the patients were maintained at all levels. 
Personal and demographic data were obtained by structured questionnaire 
 
SAMPLE COLLECTION AND PROCESSING(35,36,37): 
 Depending on the patient’s clinical features, relevant specimens were 
aseptically collected and transported to Institute of Microbiology. Observing 
standard precautions all the specimens were processed for different pathogens as 
per standard microbiological protocol for identification and/or isolation of 
pathogens. 
 
Figure 3: Specimens collected 
 
 
 Whole blood samples were collected from all the patients for CD4 count 
estimation. 
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RESPIRATORY SPECIMENS 
  Samples: Sputum (2 samples-1 spot,1early morning for AFB detection), 
Pleural fluid 
 
SPUTUM:  
1. Early morning sputum was collected after instructing the patients to gargle 
with water(38). 
2. Expectorated sputum from deep cough was collected in a sterile screw 
capped container and the outside of the container was wiped with phenol 
containing disinfectant(35). 
3. In patients who were unable to produce sputum or with high suspicion of 
PCP, induced sputum was collected by allowing the patient to inhale 
aerosolized droplets of 15% sodium chloride solution for 10mins or until a 
strong cough reflex was initiated(2). 
4. Specimen was transported within 2 hours. 
5. Sputum homogenization(38,39): The sputum was homogenized with N-
acetyl cysteine(NALC) for direct microscopy and culture. 
 
Principle: NALC is a mucolytic agent which has the ability to split the disulfide 
bonds in the mucoprotein present in the sputum and hence aid in homogenization. 
 
Stock solution prepared: 
 2.94% of Na-citrate in distilled water – autoclaved at 121°C x 15 minutes 
 0.5 g of NALC in 100 ml of Na-citrate (freshly prepared) 
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 M/15 phosphate buffer (pH 6.8-7.1) 
 
Procedure: - 
 Specimen was vortexed, equal volume of Sodium citrate and NALC was 
added to the specimen and vortexed again for 10-30seconds. The mixture was 
diluted in the phosphate buffer by adding double the volume of mixture and 
centrifuged at 1000 g for 15 minutes. The sediment was used to prepare smears 
for direct microscopy and inoculation onto appropriate media for aerobic bacterial 
and fungal culture. 
 
6. Direct microscopy:  
(i) Gram stain(35): Purulent part of the specimen was used to make a thin smear 
and Gram staining performed. Quality of the specimen was assessed  and rejected 
if >10squamous epithelial cells/low power field was seen. Smear was examined 
for polymorphonuclear cells and the predominant bacteria.  
 
(ii) KOH Mount: Sputum was mixed with equal volume of 10% KOH on a clean 
grease free glass slide, a coverslip was placed over it and observed under low and 
high power objective of the microscope for the presence of yeast cells or other 
fungal elements.   
 
(iii) ZEIHL – NEELSEN STAINING : 
Purpose: To identify acid fast bacilli in sputum suggesting Mycobacterial 
infection 
 
 A small strip of blotting paper was placed over the heat fixed smear. 
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 The filter paper was covered with primary stain, strong carbol fuchsin for 
10 minutes with intermittent heating. 
 The filter paper was removed and the slide was rinsed with water until the 
solution runs clear. 
 Decolourisation was done with 20% Sulphuric acid for 2 minutes. 
 The slide was rinsed with water and the smear covered with counter stain, 
methylene blue for 3 minutes. 
 The slide was rinsed with water and observed under oil immersion 
objective of the microscope 
 
Table 5: RNTCP Grading of the smears(40): 
No. of bacilli Result Grade 
No. of fields 
to be 
examined 
No AFB in 100 oil 
immersion fields Negative - 100 
1-9 AFB / 100 oil 
immersion fields Scanty 
Record exact 
number 200 
10-99 AFB / 100 oil 
immersion fields Positive 1+ 100 
1-10 AFB/ oil immersion 
field  Positive 2+ 50 
More than 10 bacilli / oil 
immersion field  Positive 3+ 20 
AFB-Acid Fast Bacilli 
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(iv) Direct immunofluorescent staining for Pneumocystis: 
Principle: Works on the principle of direct immunofluorescence with Fluorescent 
labelled monoclonal antibodies directed against cell wall and matrix antigen of 
P.jirovecii cysts, sporozoites and trophozoites.  
 
Procedure:  
i) Purulent part of the induced sputum was taken to make a smear on the slide 
provided and allowed to air dry 
ii) The smear was fixed in acetone for 10 minutes 
iii) Using the transfer pipette, 50µl of the detection reagent was placed on each 
well.  
iv) Slide was incubated in humid chamber for 30minutes at 37oC 
v) The slide was washed with water, dried and mounting medium placed over 
it. 
vi) The coverslip was placed and examined using fluorescence microscope. 
 
Results: Atleast two typical cysts with or without honeycomb appearance 
exhibiting apple green fluorescence was considered positive for the presence of 
P.jirovecii. 
 
7. Culture:  
  (i) Aerobic Bacterial culture: The homogenised sputum sample was 
streaked onto MacConkey agar, 5% sheep blood agar and Chocolate agar and 
incubated at 37oC for 18-24hrs with chocolate agar incubated at 5-10% CO2 in 
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Candle jar . The plates were observed for growth which were further identified by 
standard microbiological techniques. 
 
(ii) Fungal culture: The homogenised sputum sample was inoculated onto 
two Sabouraud’s dextrose agar, incubated at 25oC and 37oC and the isolates were 
further identified by standard microbiological protocol. 
 
8.GeneXpert(41): 
 Xpert MTB/RIF cartridge was labeled with the corresponding specimen 
ID. 
 1ml of expectorated sputum was transferred to a conical, screw-capped 
tube using a sterile transfer pipette.  
 2ml of  Xpert MTB/RIF Sample Reagent (2:1; v/v) was added to the 
expectorated sputum using a sterile transfer pipette, the lid was replaced 
and the tube was shaken vigorously 10-20 times.  
 The tube was allowed to stand upright for 5 min at room temperature and 
then the tube was shaken again vigorously 10-20 times 
 The tube was allowed to stand upright for another 10 min at room 
temperature. 
 The liquefied sputum sample was then transferred into the open port of the 
Xpert MTB/RIF cartridge. 
 The instrument module door with the blinking green light was opened and 
the cartridge loaded 
 The instrument was set to run and the report was generated. 
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PLEURAL FLUID: 
1. 1.Under aseptic precautions, 3-5ml of pleural fluid was collected by pleural 
tap. 2% Lignocaine was infiltrated as local anaesthesia, chest wall 
disinfected with povidone iodine, catheter inserted through the lower 
border of ribs(6-9th ribs) in the lateral side of chest and fluid collected. 
2. Macroscopic appearance of the pleural fluid was observed and recorded. 
3. The pleural fluid was centrifuged at 3000rpm per minute, supernatant 
discarded (37). 
4. Direct Microscopy: The smear made with sediment was subjected to Gram 
staining and AFB staining and interpreted. 
5. The sediment was inoculated on Mac Conkey agar, Blood agar and 
chocolate agar, incubated at 37oC for 18-24hrs, with chocolate agar 
incubated in candle jar with 5%CO2. 
6. The culture plates were examined for growth which were further identified 
as per standard microbiological protocol.  
 
STOOL SAMPLES(27):  
1. 2ml of stool sample was collected in a 25ml wide mouthed screw capped 
container with spoon.  
2. Macroscopic examination of the stool was done to look for consistency, 
presence of mucus, pus, blood and parasite.  
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3. FORMOL-ETHER SEDIMENTATION TECHNIQUE(27):   
Principle: The faecal material was dissolved in water or solutions of a density 
below that of the eggs, hence the eggs are concentrated at the bottom. 
 
Procedure(Modified Ritchief’s method):  
 1gram of faeces was emulsified in 7ml of 10%formol-saline and kept for 
10mins for fixation. 
 The mixture was then strained through a wire gauge and filtrate was 
collected in a centrifuge tube. 
 To the filtrate, 3ml of ether was added and mixed vigorously by shaking 
for 1minute, then centrifuged at 2,000rpm for 2 minutes.  
 Four layers were seen in the tube including  ether, debris, formalin and 
sediment from top 
 The debris were loosened with a stick, supernatant discarded leaving 1 or 2 
drops. 
 The deposit was mixed, a drop placed on a glass slide, coverslip placed 
over it and examined under microscope for presence of parasite. 
 
4. Direct microscopy: 
(i) Saline Mount:  
 A small quantity of faeces was mixed in a drop of saline on a clean glass 
slide, covered with coverslip and examined under low and high power objective 
of the microscope for presence of any trophozoites, protozoan cyst, eggs and 
larvae of helminths. 
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(ii)Iodine Mount:  
 Stool was emulsified in a drop of Lugol’s iodine(1:5 dilution in distilled 
water) on a clean glass slide, covered with a clean coverslip and examined under 
low and high power objective of the microscope. Parasitic forms namely 
trophozoites, protozoan cyst, eggs and larvae of helminths, when present were 
identified.  
 
(iii) Modified Acid-Fast staining for Coccidian parasite:  
Thin smear from the sediment was made on a clean glass slide, heat fixed it 
and flooded with carbol fuchsin(4g basic fuchsin+20ml 95% ethanol+8ml 
phenol+100ml distilled water). 
 
 After 9minutes, the slide was washed with water and decolorized with 5% 
aqueous sulphuric acid for 30seconds. 
 
 Washed in tap water and counterstained with 0.3%methylene blue for 
1minute. Dried and observed under oil immersion objective of microscope for the 
presence of acid fast coccidian parasites. 
 
ORAL SWAB(35):   
1. The oral cavity was examined with the use of tongue depressor and the 
lesion was identified. 
2. The lesion was swabbed with two sterile cotton swabs, taking care not to 
contaminate the swab with saliva. 
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3. One swab was used for Gram staining and observed for gram positive 
budding yeast cells with/without pseudohyphae. 
4. The other swab was inoculated onto Sabouraud’s Dextrose Agar, incubated 
at 37°C for 24-48 hours and observed for Cream coloured, smooth, pasty 
colonies.  
5. The Candida isolates were identified by Gram staining and other standard 
techniques like germ tube test, growth in CHROM agar Candida, 
chlamydospore formation and sugar fermentation test. 
 
BLOOD SAMPLES(36,37): 
1. 10ml of Blood was collected using aseptic technique from ante-cubital 
vein, inoculated into 50ml Brain Heart Infusion(BHI) broth and incubated 
at 37OC for 7days. 
2. Subcultures were done at 24hrs if there was appearance of turbidity, gas 
production or presence of microcolonies. Blind subcultures were done at 
48hrs and on 7th day of incubation irrespective of appearance of the broth. 
3. Subcultures were done on MacConkey agar and 5% sheep blood agar and 
observed for growth and isolates were identified by standard 
microbiological techniques.  
 
CSF SAMPLE(35,37): 
1. Under aseptic precaution, lumbar puncture was performed by introducing 
the spinal needle at the level of L4-L5 vertebra and 1-3ml of CSF was 
collected in a sterile screw capped tube.  
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2. Macroscopic appearance including turbidity, blood stained or presence of 
clot was noted. 
3. Sample was centrifuged at 1500rpm for 15 minutes. Supernatant was used 
for antigen detection and the sediment used for direct microscopy and 
culture. 
 
4. Direct microscopy:  
  (i) Gram stain:  Heaped up smear was made with the sediment, gram 
staining performed and observed for presence of pus cells and microorganisms. 
 (ii) KOH Mount: CSF sediment was mixed with equal volume of 10% 
KOH on a clean grease free glass slide, a coverslip was placed over it and 
observed under low and high power objective of the microscope for the presence 
of yeast cells or other fungal elements.   
(iii) India Ink Preparation: One drop of CSF sediment was mixed with 
equal volume of India ink and coverslip was placed over it to make a thin uniform 
film. The preparation was then observed under low and high power objective of 
the microscope for the presence of encapsulated yeast cells.  
(iv) Ziehl-Neelsen staining: The sediment was used to make a smear, 
Ziehl-Neelsen staining was performed and observed for presence of Acid Fast 
Bacilli. 
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5. LATERAL FLOW ASSAY FOR CRYPTOCOCCAL ANTIGEN 
DETECTION: 
 (i) Principle(18): It is a dipstick sandwich immunochromatographic assay with 
gold conjugated monoclonal antibodies against Cryptococcal polysaccharide 
coated in the form of a line on the strip, which on combining with the 
cryptococcal antigen present in the sample forms the test band.  
 
(ii) Procedure:  
 Two tubes each labelled as positive control and test were placed in a rack.  
 One drop of Lateral Flow (LF) specimen diluent was added to each tube.  
 To this one drop of CrAg positive control and 40microlitres of supernatant 
of the test CSF sample were added respectively. 
 The white end of the Cryptococcal Antigen Lateral Flow test strip was 
submerged into the test and control tube each and the strip examined after 
10minutes for the presence or absence of test and control band. 
 
(iii) Results:  
 The presence of two bands(control and test band) regardless of the 
intensity of the band is considered positive. The test was considered invalid if 
control band failed to develop.   
 
6.Culture:  
  (i) Aerobic Bacterial culture: The sediment was inoculated onto 
MacConkey agar, 5% sheep blood agar and Chocolate agar and incubated at 37oC 
for 18-24hrs with chocolate agar incubated in candle jar with 5-10% CO2. The 
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plates were observed for growth which were further identified by standard 
microbiological techniques. 
(ii) Fungal culture: The sediment was inoculated onto Sabouraud’s 
dextrose agar, incubated at 25oC and 37oC upto 4weeks. The isolates were 
identified by standard microbiological techniques. 
 
IDENTIFICATION OF MICROORGANISMS: 
IDENTIFICATION OF THE BACTERIAL ISOLATES: 
 The colonies grown on the culture media were further identified by Gram 
Staining and Biochemical reactions. 
Gram stain:- 
Using appropriate control strains microscopic examination of Gram stained 
smears prepared from the isolates was done. Based on Gram reaction, the 
organism was subjected to a set of biochemical reactions with appropriate quality 
controls. 
Biochemical reactions(35,36):  
For identification of Gram Positive cocci: 
1. Catalase 
2. Modified Oxidase test 
3. Coagulase test 
4. Urease test 
5. Aminoacid decarboxylation test (Lysine and Ornithine ) 
6. Arginine dihydrolation test 
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7. Sugar fermentation test with glucose, lactose, sucrose, maltose, mannose, 
mannitol, xylose 
8. Bile esculin test 
9. Differential discs-Novobiocin (5µg), Furazolidone (100µg), Bacitracin 
(0.04units/disk) 
 
For identification of Gram negative bacilli 
1. Hanging drop-to check for motility 
2. Catalse test 
3. Oxidase test 
4. Nitrate reduction test 
5. Indole production test 
6. Methyl red test 
7. Voges Proskaeur test 
8. Citrate utilization test 
9. Urease test 
10. Triple sugar iron agar test 
11. Sugar fermentation test Glucose, Lactose, Sucrose, maltose and mannitol 
12. Amino acid decarboxylation tests 
13. Hugh-Leifson’s Oxidation Fermentation test 
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IDENTIFICATION OF THE FUNGAL ISOLATES(25):  
Gram Stain: Creamy pasty colonies were subjected to Gram staining and 
morphology of yeast was confirmed. The yeast was further identified by the 
following algorithm. 
Figure 4: Identification of yeast isolates(25) 
 SF-Sugar fermentation; BSA-Bird Seed Agar 
Yeast isolate
India ink wet 
mount
Capsule
Cryptococcus 
neoformas Germ tube test
Cornmeal agar
Only 
blastospores
Urease test
Cryptococcus 
spp.
For Cryptococcus neoformans
1. Growth at 37ᵒC
2. Brown colony on BSA
Candida 
glabrata
Pseudohyphae, 
chlamydiospores
C.albicans. 
Confirmed by SF
Hyphae, 
arthrospores
Blastospores, 
urease test
Blastospore +, 
Urease + 
Trichosporon 
spp
Blastospore +, 
Urease -, 
Magmnusiomyces
Blastospore +, 
Urease -, 
Geotrichum 
species
Pseudohyphae, 
blastospores
Candida species (C.krusei, 
C.tropicalis, C.parapsilosis, 
C.pseudotropicalis, 
C.guilliermondii, C.albicans). 
Confirmed by CHROM agar, SF
C.albicans confirmed 
by SF
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Speciation of Candida isolates: 
1. Germ tube(Reynolds-Braude Phenomenon): The test organism was 
suspended in 0.5ml of sterile serum, incubated at 37oC for 2 hours and a drop 
from it was transferred on a glass slide. With coverslip placed over the drop, the 
slide was examined under microscope for presence of germ tube. Germ tubes 
were seen as long tube like projections extending from yeast cells without 
constriction at the point of attachment to the cell 
 
2. Cornmeal agar: Cornmeal agar with tween 80 was used for the demonstration 
of blastospores, chlamydospores and pseudohyphae. A single streak cutting the 
agar was made with a inoculating straight wire after touching the colony. Three to 
four streaks were made across the first, a coverslip was placed over it and 
incubated at 25oC for 3days. The plates were examined without lid under a 
microscope for chlamydospores, blastospores and pseudohyphae. 
 
3. Fermentation of 2% carbohydrates: For each isolate, six carbohydrate broth 
including Glucose, sucrose, lactose, maltose, galactose and trehalose were used 
with 1%peptone, 0.5% sodium chloride and Andrade’s indicator(0.005%). 
Durham’s tube was immersed in each tube for detection of gas production. Yeast 
colonies were inoculated into each broth, incubated at 25oC and examined at  
48-72 hours for acid and gas (in Durham’s tube) production. 
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Table 6: Fermentation reactions of Candida species 
Sugars C.albicans/ C.dubliniensis C.tropicalis C.krusei C.parapsilosis C.glabrata 
Glucose AG AG AG AG AG 
Lactose - - - - - 
Sucrose - AG - - - 
Maltose AG AG - - - 
Galactose V AG - V - 
Trehalose V AG - - AG 
 A-Acid G-Gas V-variable 
 
4. CHROMagar Candida: The yeast growth from SDA agar was subcultured 
onto chromogenic medium, incubated at 35oC for 24-48hours and observed for 
coloured colonies. Different coloured colonies were seen due to reaction between 
specific enzymes produced by different species and chromogenic substrate in the 
system. 
 
Table 7: Identification of Candida species on CHROMagar 
Candida species Colour 
C.albicans Light green 
C.dubliniensis Dark green 
C.glabrata Pink to purple 
C.krusei Pink 
C.parapsilosis Cream to pale pink 
C.tropicalis Blue with pink halo 
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ANTIMICROBIAL SUSCEPTIBILITY TESTING: 
The antimicrobial susceptibility testing of aerobic bacterial isolates were 
performed  as per CLSI guidelines (Clinical Laboratory Standards Institute) 
M100-S26(2016) and of fungal isolates were performed as per CLSI guidelines 
M44-A 
 
ANTIBIOTIC SUSCEPTIBILITY TESTING(42): 
 Three to five identical colonies were picked from an overnight culture with 
a sterile loop and were suspended in 0.5ml of sterile saline. After matching the 
suspension with 0.5McFarland turbidity standard, a sterile cotton tipped swab was 
dipped in the suspension and excess inoculum was drained by pressing it against 
the sides of the test tube. Lawn culture was made on Muller Hinton agar in three 
directions by rotating the plate at 60o each time and allowed to dry for 15minutes.  
The antibiotic discs were placed at equal distance and incubated aerobically at 
37oC for 18-24 hours after which the zone of inhibition was measured under 
transmitted light. The results were interpreted as per the CLSI guidelines.  
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Table 8: Antibiotic Panel for isolates of the Enterobactericeae family and 
their interpretative criteria. 
ANTIBIOTICS 
ZONE OF INHIBITION (mm) 
Sensitive Intermediate Resistant 
Ofloxacin (5 µg) ≥16 13-15 ≤12 
Ciprofloxacin (5 µg) ≥21 16-20 ≤15 
Amikacin (30 µg) ≥17 15-16 ≤14 
Trimethoprim- 
Sulphamethoxazole 
(1.25/23.75 µg) 
≥16 11-15 ≤10 
Cefotaxime (30 µg) ≥26 23-25 ≤22 
Tetracycline (30 µg) ≥15 12-14 ≤11 
Imipenem (10 µg) ≥23 20-22 ≤19 
 
Table 9: Antibiotic Panel for Acinetobacter baumannii and Pseudomonas 
aeruginosa isolates and their interpretative criteria. 
 
ANTIBIOTICS 
ZONE OF INHIBITION (mm) 
Sensitive Intermediate Resistant 
Ciprofloxacin (5 µg) ≥21 16-20 ≤15 
Ofloxacin (5 µg) ≥16 13-15 ≤12 
Amikacin (30 µg) ≥17 15-16 ≤14 
Trimethoprim/Sulfamethoxazole 
(1.25/23.75 µg) ≥16 11-15 ≤10 
Ceftazidime (30µg) ≥18 15-17 ≤14 
Tetracycline (30 µg) ≥15 12-14 ≤11 
Piperacillin-Tazobactam 
(100/10 µg) for Acinetobacter 
species 
≥21 18-20 ≤17 
Piperacillin-Tazobactam 
(100/10 µg) for Pseudomonas 
aeruginosa 
≥21 15-20 ≤14 
Imipenem(10µg) for 
Acinetobacter species ≥22 19-21 ≤18 
Imipenem(10µg) for 
Pseudomonas aeruginosa ≥19 16-18 ≤15 
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ANTIFUNGAL SUSCEPTIBILITY TESTING(43,44,45): 
 Antifungal susceptibility testing for yeast was done by disc diffusion 
method as per CLSI guidelines. Three to five colonies on SDA were emulsified in 
2ml of sterile saline and matched to 0.5McFarland turbidity standards. Lawn 
culture was made using a sterile cotton swab in three directions on Muller Hinton 
Agar plate supplemented with 2%glucose and 0.5µg/ml methylene blue, discs 
were placed on the surface of agar and incubated at 37oC for 24hours. The 
diameter of zone of inhibition was measured and compared with standard zones 
interpretive breakpoints published by CLSI M44-A2 guideline. 
 
Table 10: Antifungal panel for Candida species and their interpretive criteria 
Antifungal 
drugs Disc content 
Diameter of Zone of inhibition in mm 
Sensitive Intermediate Resistant 
Amphotericin 
B 100IU 15 10-14 <10 
Nystatin 50µg 15 10-14 10 
Fluconazole 25µg 19 15-18(DD) 14 
Ketoconazole 15 µg 28 21-27 20 
Clotrimazole 10µg 20 12-19 11 
Itraconazole 10µg 23 14-22(DD) <13 
 
DD-Dose Dependent 
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CD4 DETERMINATION BY PARTEC CYFLOW COUNTER: 
 The PARTEC CYFLOW Count System is an automated instrument 
designed for enumerating the absolute cell counts of CD4 in unlysed whole blood. 
 
Principle(18) : Works with the principle of Flow Cytometry. It simultaneously 
measures and analyses multiple physical and chemical characteristics of single 
cells as they flow in a fluid stream past optical and/or electronic sensors. It 
provides information about their relative size, granularity or internal structure and 
fluoresce in several spectral regions emitted by fluorochrome labeled probes 
which bind specifically to cellular constituents. 
 
Specimen: Under aspetic precaution,2ml of blood collected in a EDTA vacutainer 
tube  
 
Procedure: All the procedures were done observing standard precautions 
1. The tube containing the sample was mixed by inverting it 10times 
2. 20µl of whole blood was transferred to another labeled tube  
3. To it 20µl CD4 mAb PE reagent was added and incubated at room 
temperature in dark for 15minutes. 
4. Then 800µl of “no lyse buffer” was added and the tube was mixed. 
5. The sample tube was then plugged in the sample port and the start button 
was pressed to initiate the counting process. 
6. After the counting was done, the histogram generated was visualized, CD4 
region checked(Gating) and adjusted if necessary. 
7. The report of CD4 count was analysed. 
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Statistical analysis: 
 The statistical analysis was done using SPSS software. Age was presented 
as mean ± SD. The categorical variables such as gender and etiological agents 
were represented as percentages. Comparison of the mean age of the patients with 
and without opportunistic infections was done using unpaired t test. Comparison 
of the gender in patients with and without opportunistic infections was done using 
Chi square test. Comparison of the positivity of GeneXpert and Ziehl Neelsen 
staining was done using Mc Nemar’s Chi square test. Comparison of the 
opportunistic infections among the different CD4 categories and the WHO staging 
were done using Chi square test for trends. All P values < 0.05 were considered as 
statistically significant. 
  
Results 
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RESULTS 
 
 A total of 140 patients were included in this study. Of these 140 patients, 
50 (35.7%) patients had one or more than one of the laboratory proven 
opportunistic infections, while in the remaining 90 (64.3%) the etiological agents 
were not identified. 
 
Demographic details 
Table 11. Frequency distribution of age and gender: n=140 
Age range(in ages) Number of Males Number of Females Total 
18-20 Nil Nil Nil 
21-30 11 8 19 
31-40 38 24 62 
41-50 31 16 47 
51-60 8 2 10 
61-70 2 Nil 2 
Total 90 50 140 
 
Figure 5. Frequency distribution of age and gender: 
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 Age distribution 
The mean age of the patients included in this study was 39.76 ± 8.45. The 
minimum and the maximum age of the patients were 22 and 70, respectively. The 
mean ages of the patients with Opportunistic infections, with and without 
laboratory confirmation were 38.60 ± 8.10 and 40.40 ± 8.62, respectively. There 
was no statistically significant difference in the mean age of the patients with and 
without laboratory proven opportunistic infections (P value 0.228) 
 
Table 12. Comparison of gender in patients with and without laboratory 
proven opportunistic Infections (n=140) 
 
Laboratory proven 
Opportunistic Infections Total 
Yes No 
Sex 
F 19 (38.0%) 31 (62.0%) 50 (35.7%) 
M 31 (34.4%) 59 (65.6%) 90 (64.3%) 
Total 50 90 140 
 
Gender distribution 
 Of the 140 patients, 50 (35.7%) were females and 90 (64.3%) were males 
(Table12). Among the 50 female patients with HIV, 19 (38.0%) had laboratory 
proven opportunistic infections. Similarly among the 90 male patients with HIV, 
31 (34.4%) had laboratory proven opportunistic infections. There was no 
statistically significant difference in the prevalence of opportunistic infections 
between female and male patients (P value 0.813) 
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Specimens 
 A total of 142 specimens were collected from the study patients based on 
their clinical symptoms (Table 13).  
 
Table 13. Frequency distribution of the specimens (n=142) 
Type of specimen No. of samples 
Blood 9 
CSF 8 
Lymph node aspirate 4 
Oral swab 20 
Pleural Fluid 1 
Sputum 84 
Stool 16 
Total 142* 
 
* - In one patient both sputum and CSF were collected and in another patient both 
sputum and oral swab were collected.  
 
Figure 6: Frequency distribution of the specimens 
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Opportunistic infections 
 Of the 140 patients, 50 (35.7%) patients had laboratory proven 
opportunistic infections. The etiological agents of the opportunistic infections are 
summarised in Table 16. 48 patients had one opportunistic infection each. Two 
patients had dual opportunistic infections. One patient had Pulmonary tuberculosis 
and Oral Candidiasis while another patient had Tuberculous Meningitis and 
Bronchopneumonia caused by Klebsiella pneumoniae. The distribution of 
bacterial, fungal and parasitic causes of opportunistic infections is depicted in 
Figure 7. 
 
Figure 7. Distribution of bacteria, fungi and parasitic causing opportunistic 
infections (n=52) 
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Table 14. Profile of Bacterial pathogens causing OIs: (n=30) 
Clinical Diagnosis Samples Pathogen No. of pathogen 
Percentage 
(%) 
Pulmonary 
Tuberculosis Sputum Mycobacteria 21 70 
Bronchopneumonia Sputum K.pneumoniae 4 13.3 
Bronchopneumonia Sputum P.aeruginosa 1 3.3 
Meningitis CSF Mycobacteria 3 10 
Cold abscess 
Lymph 
node 
aspirate 
Mycobacteria 1 3.3 
 
Figure 8: Profile of Bacterial pathogens causing OIs 
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Table 15. Profile of Fungal pathogens causing OIs(n=21) 
Clinical Diagnosis Samples Pathogen No. of pathogen(n=21) 
Percentage 
(%) 
Bronchopneumonia Induced sputum P.jirovecii 1 4.7 
Oral thrush 
 Oral swab 
Candida 
albicans 12 57.1 
Candida 
tropicalis 3 13.3 
Candida 
dubliniensis 1 4.7 
Candida krusei 1 4.7 
Candida 
parapsilosis 1 4.7 
Meningitis CSF Cryptococcus neoformans 2 9.5 
 
Figure 9:Profile of Fungal pathogen causing OIs (n=21) 
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Profile of Parasite causing Opportunistic infections: 
  Among the 52 patients with opportunistic infections, Strongyloides 
stercoralis was demonstrated in stool sample of 1 patient with diarrhea.  
 
Table 16. Cumulative profile of etiological agents causing opportunistic 
infections (n=52) 
 Frequency Percentage (%) 
Bacteria   
Mycobacteria 25 48.08 
Klebsiella pneumoniae 4 7.69 
Pseudomonas aeruginosa 1 1.92 
Fungi   
Candida albicans 12 23.08 
Candida dubliniensis 1 1.92 
Candida krusei 1 1.92 
Candida parapsilosis 1 1.92 
Candida tropicalis 3 5.77 
Cryptococcus neoformans 2 3.85 
Pneumocystis jirovecii 1 1.92 
Parasite   
Strongyloides stercoralis 1 1.92 
Total 52  
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 Bacterial opportunistic infections were the most common OIs seen in 
PLHA of which Mycobacterium tuberculosis was the most predominant pathogen 
responsible for 48% of opportunistic infections followed by fungal opportunistic 
infections by Candida species accounting for 34%. Among the Candida species, 
Candida albicans was the most common species responsible for OI. 
 
Figure 10: Cumulative profile of etiological agents causing opportunisic 
infections 
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Table 17. Sample wise distribution of M.tuberculosis(n=25) 
Sample (n=25) Frequency Percentage 
Sputum 21 84% 
Lymph Node 1 4% 
CSF 3 12% 
 
 Among tuberculosis infection, Pulmonary tuberculosis was more common 
(84%) compared to extrapulmonary tuberculosis (16%). Among extrapulmonary 
tuberculosis, tuberculous meningitis was more common 
 
Figure 11:Sample wise distribution of M.tuberculosis 
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Table 18. Comparison of the positivity of GeneXpert and Ziehl Neelsen 
staining (n=37) 
 
 
GeneXpert 
Total 
Positive Negative 
ZN 
Positive 12 (32.4%) 0 (0.0%) 12 (32.4%) 
Negative 5 (13.5%) 20 (54.1%) 25 (67.6%) 
Total 17 (45.9%) 20 (54.1%) 37 
 
 Out of the 37 samples (Sputum, CSF and Lymph node aspirate) tested,  
17 (45.9%) were positive for M. tuberculosis by GeneXpert, while only 12 
(32.4%) were positive by ZN staining. GeneXpert contributed to detection of 
additional 5 cases of TB. The difference in the positivity of GeneXpert and ZN 
staining was only marginally significant (P value 0.063). 
 
Table 19. Antibiotic susceptibility Pattern of Bacterial Pathogens (n=5) 
Organism AK OF CIP COTRI CTX CAZ PT TET IMP 
K.pneumoniae 
(n=4) 100% 100% 75% 75% 50% - - 100% 100% 
P.aeruginosa 
(n=1) 100% 100% 100% - - 100% 100% - 100% 
 
AK-Amikacin; OF-Ofloxacin; CIP-Ciprofloxacin; CTX-Cefotaxime;  CAZ-Ceftazidime;       
PT- Piperacillin-tazobactam; TET- Tetracycline;  IMP-Imipenem 
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 Of the 4 Klebsiella pneumoniae isolates, 2 were Extented Spectrum -
Lactamase (ESBL) producers 
 All the M.tuberculosis detected by GeneXpert from the 17 samples were 
sensitive to Rifampicin 
 
Table 20. Antifungal susceptibility Pattern of Fungal Pathogens(n=20) 
Fungal species Ampho tericin B Nystatin 
Fluco 
nazole 
Keoto 
conazole 
Clotri 
mazole 
Itra 
conazole 
Candida albicans 
(n=12) 100% 100% 91.6% 91.6% 100% 91.6% 
Candida tropicalis 
(n=3) 100% 100% 100% 100% 100% 100% 
Candida 
dubliniensis (n=1) 100% 100% 100% 100% 100% 100% 
Candida krusei 
(n=1) 100% 100% -* 100% 100% 100% 
Candida 
parapsilosis (n=1) 100% 100% 100% 100% 100% 100% 
*C.krusei  is intrinsically resistant to Fluconazole 
 
 Among the 12 Candida albicans tested, 10 isolates were susceptible to all 
the antifungals. Out of the two resistant isolates, one was resistant to ketoconazole 
and Flucanazole, and the other was resistant to Itraconazole 
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Table 21. Association of WHO stage and opportunistic infections(n=140) 
 
Opportunistic Infections 
P value 
Yes No 
WHO Stage 
II 2 (12.5%) 
14 
(87.5%) 
0.091 
III 14 (34.1%) 
27 
(65.9%) 
IV 34 (41.0%) 
49 
(59.0%) 
Total 50 90 
 
 The prevalence of opportunistic infections showed an increasing trend with 
increase in WHO stage. 
 
Table 22. Association of CD4 count and opportunistic infections (n=140) 
 
Laboratory proven 
Opportunistic Infections P value 
Yes No 
CD4 Cell 
Count 
<200 39* (50.6%) 38 (49.4%) 
<0.0001 
200 - 499 10 (23.3%) 33 (76.7%) 
≥ 500 1 (5.0%) 19 (95.0%) 
Total 50 90 
*Out of 39, 2 patients had 2 laboratory proven opportunistic infections 
 
 The CD4 cell counts were analyzed according to CDC category and 
correlated with opportunistic infections. The prevalence of opportunistic 
infections showed an increasing trend with decrease in CD4 count. There was 
significant association between CD4 count and the prevalence of opportunistic 
infections (P value <0.0001).  
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Figure 12:Association of CD4 count and opportunistic infections 
 
 
 
Table 23. Association of CD4 count and candidiasis (n=140) 
 
Candidiasis 
P value 
Yes No 
CD4 Cell 
Count 
<200 16 (20.8%) 61 (79.2%) 
0.007 
200 – 499 2 (4.7%) 41 (95.3%) 
≥ 500 0 (0%) 20 (100.0%) 
Total 18 122 
 
There was significant association between CD4 count and the prevalence 
of candidiasis (P value 0.007). Of the 18 patients with candida infections, 16 
patients had CD4 count < 200 cells/ µl, while 2 patients had CD4 count between 
200 – 499 cells/ µl. Candida infection was not found in the 20 patients with CD4 
count ≥ 500 cells/ µl. 
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Figure 13: Association of CD4 count and candidiasis (n=140) 
 
 
Table 24. Association of CD4 count and Mycobacterial infections (n=140)  
 
Mycobacterial Infection 
P value 
Yes No 
CD4 Cell 
Count 
<200 19 (24.7%) 58 (75.3%) 
0.05 
200 - 499 5 (11.6%) 38 (88.4%) 
≥ 500 1 (5.0%) 19 (95.0%) 
Total 25 115 
 
 The prevalence of Mycobacterial infections showed an increasing trend 
with decrease in CD4 count and this association was significant (P value 0.05) 
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Figure 14: Association of CD4 count and Mycobacterial infections 
 
 
 
Association of CD4 count and other opportunistic infections 
 The CD4 count of the 2 patients with Cryptococcal meningitis was 32 and 
210 cells/ µl. The CD4 count of the patient with Pneumocystis jirovecii 
Pneumonia was 34 cells/ µl. The CD4 count of the patient with Strongyloides 
stercoralis infection was 41 cells/ µl. Out of the 4 patients with Klebsiella 
pneumonia causing bronchopneumonia, 3 had CD4 count <200 cells/ µl, while 
one patient had a count of 258 cells/ µl.  
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DISCUSSION 
 
 In People living with HIV/AIDS, the morbidity and mortality is mainly due 
to opportunistic infections which take advantage of the lowered cellular and 
humoral defence mechanisms of the patient. The infections encountered in PLHA 
vary widely including those caused by bacteria, fungi, viruses and parasites. 
Tuberculosis (TB) is the most common life-threatening opportunistic infection 
affecting PLHA as per the World Health Organisation(WHO) report 2015 
particularly in India(46,2).  
 
AGE DISTRIBUTION:  
 The mean age of the patients included in the present study was 39.76±8.45 
years.  
 
GENDER DISTRIBUTION:   
 Though males(64.3%) were predominant in the study group, there was no 
statistically significant gender difference between laboratory proven and unproven 
cases with opportunistic infection.   
 
OPPORTUNISTIC INFECTIONS: 
 In the present study, Tuberculosis(48%) was observed to be the most 
frequent opportunistic infection followed by Candidiasis(34.6%), 
Bronchopneumonia caused by Klebsiella pneumoniae (7.7%), Cryptococcal 
meningitis(3.85%), Bronchopneumonia caused by Pseudomonas aeruginosa 
88 
 
(1.9%), Pneumocystis jirovecii Pneumonia (1.9%) and Strongyloidosis  
stercoralis (1.9%).   
 
 Despite being preventable and curable, tuberculosis (TB) is the leading 
cause of death from infectious disease globally, with nearly 10 million people 
developing TB and 1.5 million people dying from TB in 2014(46). TB is the 
leading cause of morbidity and mortality among people living with HIV 
worldwide, with 1.2 million new HIV-infected persons reported with TB and 
3,90,000 deaths in 2014(6). Tuberculosis was the most prevalent OI reported in 
this study accounting to 48%, similar to the studies done by Vandana Dabla, et al. 
at Delhi 2014 and Shahapur, et al. at Karnataka 2009 who reported the prevalence 
of  28.7% and 43.6% respectively whereas Sangeeta, et al. at Ahmedabad reported 
Candidiasis as predominant pathogen with the prevalence of 32.67% followed by 
Tuberculosis(22.71%)(47,48,49)). Candidiasis being a frequent infection among 
PLHA, has been documented in upto 70% of the patients infected with HIV(2). In 
the current study, the second most common OI among PLHA was Candidiasis 
with a prevalence of 34.61% similar to the study by Vandana Dabla, et al. who 
reported Candidiasis as the second most common OI(47). 
 
BACTERIAL OPPPORTUNISTIC INFECTIONS:  
 Bacterial infection was seen most commonly in patients with respiratory 
tract infections. Diseases like bacterial pneumonia occur at a higher rate in HIV 
infected people than in general population(50). In this study M.tuberculosis 
(83.3%) was the commonest bacterial pathogen causing OI followed by Klebsiella 
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pneumoniae (13.3%) and Pseudomonas aeruginosa (3.3). This finding was similar 
with the observation of Sangeeta, et al. Ahmedabad where M.tuberculosis 
followed by Klebsiella pneumoniae and Pseudomonas aeruginosa were the 
common bacterial opportunistic pathogens in PLHA though there was a slight 
difference in their distribution namely M.tuberculosis (60.5%), Klebsiella 
pneumoniae (15.7%), Pseudomonas aeruginosa (10.5%), S.aureus (7.8%) and 
Escherichia coli (1.9%)(49).  
 
FUNGAL OPPORTUNISTIC INFECTIONS: 
 The most common fungal pathogen causing OI in PLHA was Candida 
species(85.7%) followed by Cryptococcus species (9.5%) and Pneumocystis 
jirovecii (4.7%).  
 
 The Candida species were isolated from Oral thrush in PLHA. Oral 
Candidiasis is a common oral manifestation in PLHA and is the second most 
common opportunistic infection in PLHA from India(2) as with the present study, 
though in study done by  Sangeeta, et al., Candidiasis was reported as the most 
common OI. Out of 18 Candida species isolated from oral lesions, 12 were 
Candida albicans(66.6%) while 6 were non albicans Candida species(33.3%) 
which were consistent with other studies done by Sangeetha, et al., Nadeem, et al., 
Francis, et al. and Kaur, et al.(49,51,52). 
 
 Cryptococcus neoformans was isolated from 2 out of 5 PLHA with 
meningitis. In the present study Cryptococcus infections is the second most 
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common fungal infection accounting to 9.5%. There were no Pulmonary 
Cryptococcosis recorded in this study. 
Though PCP is one of the most common opportunistic infection in PLHA living 
in industrialised nation, its prevalence is rare in tropical and developing 
countries(53). In the present study the prevalence of PCP was 1.92%.  
 
PARASITIC OPPORTUNISTIC INFECTIONS:  
 In the present study, 16 patients presented with mild to moderate diarrhoea. 
Strongyloides stercoralis was demonstrated from one patient whose CD4 count 
was 41cells/µl. 
 
TUBERCULOSIS 
 According to the WHO report 2015, TB has become one of the leading 
cause of death among HIV infected patients killing almost three fourth of affected 
cases(54). In the current study, out of 25 cases reported as TB, 84% were 
Pulmonary infection while 16% were extrapulmonary infection similar to the 
findings in Ajay kumar, et al., from South India(55) though Kumarasamy, et al. in 
his study reported higher prevalence of extra pulmonary tuberculosis than 
pulmonary which is contrary to this study(56).  
 
 Comparison of positivity of GeneXpert and Ziehl Neelsen staining: 
Monika, et al. estimated the sensitivity and specificity of GeneXpert were 86.8% 
and 93.1% respectively while that of ZN staining were 22.2% and 78.5%(57). In 
the present study 37 samples(including Sputum, CSF, Lymph node aspirate) with 
suspected TB were subjected to both GeneXpert and Ziehl Neelsen(ZN) staining. 
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Of these samples 45.9% were positive by GeneXpert, while only 32.4% were 
positive by ZN staining.  
 
 All the M.tuberculosis detected by GeneXpert (17)  were sensitive to 
Rifampicin 
 
ORAL CANDIDIASIS: 
 Among the 18 Candida isolated from Oral thrush of PLHA, Candida 
albicans was the most frequently isolated species accounting to 66.6%, followed 
by C.tropicalis (16.6%), C.dubliniensis (5.5%), C.krusei (5.5%) and 
C.parapsilosis (5.5%).  
 
 Isadora, et al. Mexico, demonstrated the same with C.albicans(71.8%) 
being the most common species followed by C.tropicalis(12.2%), 
C.glabrata(8.3%), C.parapsilosis(2.2%), C.krusei(1.7%) and 
C.guilliermondii(1.1%) (58).  
 
Faseela, et al., Karnataka(59), the study done with 40 Candida isolates from 
oral thrush 60% were C.albicans and was the predominant species, followed by 
15% C.tropicalis, 10% C.glabrata, 5% C.dubliniensis, 5% C.krusei, 2.5% 
C.lusitaniae and 2.5% C.parapsilosis which was similar to the findings in the 
present study.  
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ANTIBIOTIC SUSCEPTIBILITY PATTERN OF BACTERIAL 
PATHOGEN:  
 Among the 4 Klebsiella pneumoniae isolated from sputum sample of 
PLHA with bronchopneumonia, 2 were Extended Spectrum Betalactamase 
producers while the other 2 Klebsiella pneumoninae and the Pseudomonas 
aeruginosa were susceptible to all the antibiotic drugs tested as per CLSI 
guidelines. 
 
ANTIFUNGAL SUSCEPTIBILTY PATTERN OF FUNGAL PATHOGEN 
 Though Candida albicans was the most frequent pathogenic species 
isolated from oral lesions, other non-albicans Candida species have become a 
significant cause of infection in PLHA in this study. The clinical importance of 
these non-albicans Candida species lies in the fact that they are usually less 
susceptible to the more commonly used azole antifungal drugs(25). 
 
 The Antifungal susceptibility test performed in this study revealed that 
among 12 C.albicans, 10 isolates were sensitive to all the antifungals tested while 
2 were resistant of which, 1 isolate was resistant to Fluconazole and Ketaconazole 
and the  other isolate was resistant to itraconazole. All the non-albicans Candida 
isolates were sensitive to all the antifungals tested. 
 
 In the study done by Faseela, et al., in Karnataka, she demonstrated that 
29% of C.albicans were resistant to Fluconazole and 1 C.tropicalis showed 
resistance to Amphotericin B while others were sensitive(59).  
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WHO STAGING AND OPPORTUNISTIC INFECTION: 
 The Clinical staging is based on the clinical findings that aid in the 
diagnosis, evaluation, and management of HIV/AIDS. It does not require CD4 
cell count, hence is used in countries to determine eligibility to initiate ART and 
assess the severity of the disease especially in the settings where CD4  testing 
facility is not available.  
 
 In the present study, the prevalence of opportunistic infections showed a 
proportional increase with increase in WHO clinical Stage though the association 
lacked to demonstrate any statistical significance.  
 
ASSOCIATION OF CD4 COUNT AND OPPORTUNISTIC INFECTIONS: 
 In the current study, the prevalence of opportunistic infections showed an 
increasing trend with decrease in CD4 cell count which was statistically 
significant having the mean CD4 count of 243cells/µl in PLHA with OI being. 
This finding depicts that depletion of CD4 cell results in incidence of more 
opportunistic infection.   
 
ASSOCIATION OF CD4 COUNT AND CANDIDIASIS: 
 The mean CD4 cell count in PLHA with Candidiasis was 139cells/µl.  
There was significant association between decrease in CD4 count and prevalence 
of Candidiasis in the present study. Most of the studies including Ajay kumar, et 
al.,(55) reported candidiasis in PLHA at CD4 count <200cells/µl(9) which is same 
as the findings in the present study except 2 patients in whom Candidiasis was 
seen at CD4 count 328 and 210 cells/µl.  
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ASSOCIATION OF CD4 COUNT AND MYCOBACTERIAL 
INFECTIONS: 
 TB incidence doubles in the first year following HIV infection and can 
occur at any CD4 cell count, though the risk increases with progressive 
immunodeficiency(6). Pulmonary tuberculosis is more common at CD4 count 
between 200-500cells/µl while disseminated and extrapulmonary TB at less than 
<200cells/µl(2). 
 
 In the present study also the prevalence of tuberculosis showed an 
increasing trend with decrease in CD4 cell count and the association was analysed 
to be significant. The mean CD4 count observed in cases of Pulmonary 
tuberculosis and extrapulmonary tuberculosis were 146cells/µl and 231cells/µl 
which was on par with the findings of Ajay kumar, et al., and Shahapur, et al(55,60).  
 
MORTALITY:  
 Mortality was observed in 3 patients included in the study where 2 patients 
had Tuberculous Meningitis and the other one diagnosed with Cryptococcal 
meningitis.  
 
  
Summary 
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SUMMARY 
 
 140 PLHA with symptoms of OIs were included in the study after 
informed written consent.  
 Of the 140 PLHA recruited, etiological agents causing opportunistic 
infection was identified in 50 PLHA with two patients showing dual 
infection. 
 Among the opportunistic infections identified, Tuberculosis was the 
predominant OI in PLHA with the prevalence of 48% followed by 
Candidiasis(34.6%), Bacterial bronchopneumonia (9.6%), Cryptococcal 
meningitis(3.85%), Pneumocystis jirovecii pneumonia (1.9%) and 
Strongyloidosis(1.9%). 
 In the present study, Pulmonary tuberculosis was more common than 
extrapulmonary tuberculosis.  
 GeneXpert was more sensitive in detecting tuberculosis infection compared 
to Ziehl Neelsen staining. 
  The Mycobacterium tuberculosis identified by GeneXpert were all 
sensitive to Rifampicin. 
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 Among the 4 Klebsiella pneumoniae isolated from sputum sample of 
patients with bronchopneumonia, 2 were Extended Spectrum 
Betalactamase (ESBL) producers. Other bacterial isolates were sensitive to 
all drugs. 
 Candida albicans(66.6%) was the most commonly isolated Candida 
species from Oral thrush compared to non-albicans Candida 
species(33.3%). 
 Among the non-albicans Candida species isolated from oral lesions, 
C.tropicalis was predominant(3/6), while C.dubliniensis, C.krusei and 
C.parapsilosis were isolated one each. 
 The antifungal susceptibility testing of the Candida species revealed that 
one C.albicans was resistant to Fluconazole and Ketaconazole while 
another was resistant to Itraconazole. Other C.albicans and non-albicans 
Candida were susceptible to all the antifungal drugs tested except C.krusei 
which is intrinsically resistant to Fluconazole. 
 Two Cryptococcus neoformans were isolated from CSF in patients 
presenting with meningitis.  
 Strongyloides stercoralis was identified in one patient with diarrhoea. 
 The prevalence of OIs showed an increasing trend with increase in WHO 
clinical staging. 
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 Prevalence rate of opportunistic infections showed significant association 
of increasing trend with decrease in CD4 cell count. 
 Prevalence of Candidiasis was more common in patients with CD4 count 
<200cells/µl and revealed statistically significant association. 
 Prevalence of Mycobacterial infection showed increasing trend with 
decrease in CD4 cell count.    
 Mortality was observed in 3 patients included in the study where 2 patients 
had Tuberculous Meningitis and the other one diagnosed with 
Cryptococcal meningitis.  
  
Conclusion 
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CONCLUSION 
 
The emergence and pandemic spread of AIDS constitute the greatest 
challenge to public health in modern time. With the changing scenario of AIDS 
epidemic, opportunistic infections add to the  endemicity of the already existing 
infections like tuberculosis. The present study reflects that Tuberculosis followed 
by Candidiasis were the most common OIs seen in PLHA and the risk of OI 
increases with decrease in CD4 count. Hence this study proves that the spectrum 
of opportunistic infections among various patient groups varies significantly. 
Prompt HAART initiation, along with monitoring patients for OIs with decreasing 
CD4 count, initiating OI prophylaxis, early diagnosis and treatment of OIs will aid 
in decreasing the morbidity and mortality of the PLHA. 
Colour plates 
  
COLOUR PLATES 
 
Colour Plate 1: Ziehl-Neelsen staining of Lymph Node aspirate showing Acid 
Fast Bacilli 
 
Colour Plate 2: Phenotypic test for the detection of ESBL production by 
Combined Disc method. 
 
 
  
Colour Plate 3: Germ tube production by C.albicans 
 
 
Colour Plate 4: CHROMagar candida 
  
  
Colour Plate 5 : 2% carbohydrate fermentation test showing  
reaction for C.albicans 
 
 
Colour Plate 6: 2% carbohydrate fermentation test showing  
reaction for C.tropicalis 
 Colour Plates 7: Refractile single terminal Chlamydospore  
of C.albicans on Corn Meal Agar 
 
 
Colour Plates 8: Pseudohyphae with elongated blastoconidia (with cross-match 
stick appearance) of C.krusei on Corn Meal Agar 
 Colour Plate 9: Antifungal susceptibility testing by Disc Diffusion method 
 
 
Colour Plate 10: CSF Gram stain of PLHA with meningitis showing 
capsulated Gram positive round budding yeast cells. 
 
Colour Plate 11: India ink stain of CSF from patient with meningitis showing 
capsulated round budding yeast cells. 
 
 
Colour Plate 12: Lateral Flow Assay for Cyptococcal Antigen on CSF with 
meningitis showing positive test 
  
  
Colour Plate 13: Cryptococcus neoformans showing brown coloured colonies 
on Bird Seed Agar 
 
 
Colour Plate 14: Stool Wet Mount showing Rhabditiform larvae of 
Strongyloides stercoralis 
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ANNEXURE -1 
 
LIST OF ABBREVIATIONS 
 
ADCC - Antibody Dependent Cell Mediated cytotoxicity 
AFB - Acid Fast Bacilli 
AIDS - Acquired Immuno Deficiency Syndrome 
ART - Anti-Retroviral Therapy 
BHI - Brain Heart Infusion 
CCR5 - C-C Chemokine receptor R5 
CD - Cluster of Differentiation 
CDC - Centre for Disease Control 
CLSI - Clinical Laboratory Standards Institute 
CSF - Cerebrospinal Fluid 
CXCR4 - Co-receptor X4 
DNA - Deoxy Ribonucleic acid 
EDTA - Ethylene Diamine Tetra Acetic Acid 
ELISA - Enzyme Linked Immunosorbent Assay 
ESBL - Extended Spectrum Betalactamase 
FDC - Follicular Dentritic Cells 
GALT - Gut Associated Lymphoid Tissue 
GRID - Gay-related immune deficiency 
HAART - Highly Active Anti-retroviral Therapy 
HIV - Human Immunodeficiency Virus 
HTLV - Huma T-cell leukemia virus  
ICTC - Integrated Counselling and Testing Centre 
IRIS - Immune Reconstitution Inflammatory Syndrome 
KOH - Potassium hydroxide  
  
 LAV - Lymphadenopathy-associated Virus 
LTR - Long Terminal Repeat 
LTNP - Long Term Non Progressor 
NACO - National AIDS Control Organization 
NALC - N-acetyl L-cysteine 
NNRTI - Non-Nucleoside Reverse Transcriptase Inhibitor 
NRTI - Nucleoside Reverse Transcriptase Inhibitor 
NTM - Non-tuberculous Mycobacteria 
OIs - Opportunistic Infections 
PCP - Pneumocystis jirovecii Pneumonia 
PCR - Polymerase Chain Reaction 
PI - Protease Inhibitor 
PLHA - People Living with HIV and AIDS 
RNA - Ribonucleic Acid 
RT - Reverse Transcriptase 
SDA - Sabouraud dextrose agar 
SPSS - Statistical Package for Social Sciences 
TB - Tuberculosis 
UNAIDS - The Joint United Nations Programme on HIV and AIDS 
WHO - World Health Organization 
 
  
ANNEXURE – II 
 
PROFORMA 
 
 Name :                                                                      IP/OP  NO: 
 Age:                                                                           
 Sex:                  
 Occupation: 
 Address: 
 Clinical Diagnosis: 
 
 Presenting complaints 
 
 
 
 Personal history 
 
 
 Past history 
 
 Co-morbid conditions, if any: 
 
 Prior antimicrobial  therapy 
 
 CD4 count: 
 
 WHO Clinical stage: 
 
 
 Microbiological  investigation: 
 
 
 Antibiotic or Antifungal sensitivity pattern:- 
 
 
 
  
ANNEXURE-2 
 
 
CONSENT FORM 
 
 
STUDY TITLE : Prevalence and profile of Bacterial, Fungal And Parasitic 
   Opportunistic infections in People Living With HIV/AIDS 
 
 I…………………………………………, hereby give consent to participate in 
the study conducted  by Dr.C. Justine Auxilia Irene, Post graduate at Institute of 
Microbiology, Madras Medical College, Chennai and to use my personal clinical data 
and the result of investigations for the purpose of analysis and to study the nature of the 
disease, I also give consent to give my clinical Specimen (sputum, endotracheal aspirate, 
bronchial wash, pleural fluid, stool, oral swab, blood, cerebrospinal fluid) for further 
investigations. I also learn that there is no additional risk in this study. I also give my 
consent for my investigator to publish the data in any forum or journal. 
 
   
Signature/ Thumb impression                                   Place                             Date 
Of the patient/ relative 
 
Patient Name & Address: 
 
Signature of the investigator: 
 
Signature of  guide 
 
  
ANNEXURE-3 
 
INFORMATION SHEET 
 
STUDY TITLE : Prevalence of Bacterial, Fungal And Parasitic Opportunistic 
infections in People Living With HIV/AIDS 
 
INVESTIGATOR  : Dr.C.Justine Auxilia Irene, 
                                    Post Graduate, 
    Institute of Microbiology, 
  Madras Medical College, Chennai - 600003. 
 
GUIDE   : Dr. U.Umadevi, 
                                      Professor of Microbiology, 
                                      Institute  of  Microbiology, 
                                      Madras  Medical  College, Chennai  600 003. 
 
 Progressive destruction of immune system by chronic HIV infection leading to 
progressive fall in the level of CD4 cells (<200/μl to <50 / μl) is known to be responsible for the 
occurrence of infections by a variety of opportunistic microorganisms. In HIV infection 
Opportunistic Infections (OIs) account for a considerable proportion of mortality and morbidity . 
This is also responsible for the recurrent, prolonged, intractable and severe nature of infection in 
HIV seropositive individuals.  
 
The incidence of OIs depends on the level of immunosuppression and on the endemic 
prevalence of the pathogen. The organism causing OIs usually cause asymptomatic or mildly 
symptomatic, self limiting infections in immunocompetent individuals whereas in HIV infected 
patients, these infections may be severe or even life threatening. 
 
Despite the availability of ART, OIs continue to cause considerable morbidity and 
mortality because of issues of non-adherence, ART drug resistance and treatment failure. 
Knowledge of the pattern of opportunistic infections can often guide therapy when resource 
limitations hamper the exact diagnosis of the etiological agent. HIV/AIDS may not be curable 
but most of the opportunistic infections can be effectively treated. Prophylaxis against some of 
these infections will not only prolong the life of an HIV infected individual but also improve the 
quality of life 
.  
The type of pathogens responsible for OIs varies from country to country and even from 
region to region within the same country . Therefore it is important to know the relative 
frequencies of specific OIs in different parts of the country for appropriate management 
strategies. Considering this fact, the present study is to be conducted to determine the prevalence 
of bacterial, parasitic, fungal infections in HIV seropositive patients, to assess the pattern of 
sensitivity of the isolates 
 
This study is entirely voluntary and patient can withdraw any time from this study. Extra 
cost will not be incurred to the patients in this study. Confidentiality of the patient’s detail will be 
maintained at all level. Any queries regarding this study will be willingly clarified. Results of the 
study will be published. In case of any doubts please contact Dr.C.Justine Auxilia Irene 
 
  
S.No IP. No AGE SEX CLINICAL PRESENTATION
WHO 
STAGE
CD4 
COUNT
SAMPLE ORGANISM RIF AK OF CIP COTRI CTX CAZ PT TET IMP AMP B NYS FLU
CLO 
TRI
KETA ITRA
1 61511 29 F Headache IV 210 CSF
Cryptococcus 
neoformans
2 63757 46 M Fever IV 336 Blood NIL
3 81146 50 M Fever, cough IV 352 Sputum NIL
4 79954 55 M Headache, altered sensorium IV 432 CSF Mycobacteria S
5 84583 50 F Cough with expectoration IV 512 Sputum NIL
6 85122 45 F Acute diarrhea IV 95 Stool NIL
7 68095 38 M Fever, cough IV 92 Sputum Mycobacteria S
8 67293 50 M Fever IV 223 Blood NIL
9 68926 30 M Chronic diarrhea III 133 Stool NIL
10 79780 37 M Chronic diarrhea IV 41 Stool
Strongyloides 
stercoralis
11 90027 29 F Cough with expectoration II 536 Sputum NIL
12 90197 50 F Cough with expectoration III 452 Sputum NIL
13 94878 35 F Fever, cough with expectoration II 258 Sputum K.pneumoniae S S S S S S S
14 95398 45 M Breathlessness, cough IV 342 Sputum NIL
15 91427 38 F Cough with expectoration III 190 Sputum NIL
16 95394 42 M Acute diarrhea III 236 Stool NIL
17 94808 52 M Fever, cold abscess IV 410
Lymph node 
aspirate
Mycobacteria S
18 98188 40 M Fever, cough with expectoration IV 77 Sputum NIL
19 96963 40 M Cough with expectoration III 259 Sputum NIL
20 99169 40 M Oral thrush IV 35 oral swab C.albicans S S S S S S
21 92236 28 M Fever, Headache IV 34 CSF Mycobacteria S
22 105729 45 M Fever, cough with expectoration III 459 Sputum P.aeruginosa S S S S S S
23 105218 35 F Cough with expectoration III 197 Sputum K.pneumoniae S S R R S S S
24 105499 43 M Fever, breathlessness IV 34 Sputum Mycobacteria S
25 102027 37 M Fever, cough III 539 Sputum NIL
26 107680 48 M Cough with expectoration III 251 Sputum NIL
27 115140 26 M Cough II 587 Sputum NIL
28 10302 38 M Breathlessness, cough II 544 Sputum NIL
29 107928 45 M Fever, breathlessness IV 34 Sputum P.jirovecii
30 11070 39 M Fever, altered  sensorium IV 133 CSF NIL
31 10962 45 F Oral thrush III 328 oral swab C.albicans S S S S S S
32 11959 32 F Fever, cough with expectoration IV 86 Sputum NIL
33 10872 50 F Fever, breathlessness III 445 Sputum NIL
34 18479 40 M Cough with expectoration III 630 Sputum NIL
35 18462 40 M Cough with expectoration IV 450 Sputum NIL
36 17350 50 M Chest pain, breathlessness IV 344 Sputum NIL
37 14212 36 M Cough with expectoration IV 137 Sputum NIL
38 13429 29 M Oral thrush IV 119 oral swab C.tropicalis S S S S S S
39 15928 40 M Cough IV 47 Sputum NIL
40 13804 36 F Breathlessness, cough IV 123 Sputum NIL
41 17552 28 F
Fever, cough with expectoration, oral 
thrush
IV 155
Sputum, Oral 
swal
Mycobacteria, 
C.tropicalis
S S S S S S
42 21238 43 M Fever, breathlessness IV 126 Sputum NIL
43 22469 35 F Cough with expectoration IV 512 Sputum NIL
44 22178 36 F Cough with expectoration IV 450 Sputum NIL
45 110501 32 M Fever, chest pain IV 321 Sputum NIL
46 17592 50 M Breathlessness, cough III 161 Sputum Mycobacteria S
47 23746 40 F Cough with expectoration IV 123 Sputum NIL
48 23406 55 M Fever, cough IV 542 Sputum NIL
49 29913 40 M Fever, breathlessness IV 57 Sputum NIL
50 21633 34 F Breathlessness, cough III 228 Sputum NIL
ANNEXURE IV - MASTER CHART
S.No IP. No AGE SEX CLINICAL PRESENTATION
WHO 
STAGE
CD4 
COUNT
SAMPLE ORGANISM RIF AK OF CIP COTRI CTX CAZ PT TET IMP AMP B NYS FLU
CLO 
TRI
KETA ITRA
51 23947 42 F Fever, hemoptysis III 354 Sputum Mycobacteria S
52 26087 46 M
Fever, headache, cough with 
expectoration
IV 51 CSF,Sputum
Mycobacteria, 
K.pneumoniae
S S S S S R S S
53 28782 22 F Fever, cough IV 423 Sputum NIL
54 30354 45 F Breathlessness, chest pain IV 145 Sputum NIL
55 28521 40 M Fever, cough with expectoration III 211 Sputum Mycobacteria
56 29116 63 M Fever, loss of appetite IV 127 Sputum NIL
57 5727 56 F Loss of appetite, breathlessness III 125 Sputum NIL
58 5385 34 F
Fever, fatigue, cough with 
expectoration
II 154 Sputum NIL
59 5676 40 F Cough with expectoration IV 58 Sputum Mycobacteria S
60 5872 46 F Breathlessness, cough IV 340 Sputum NIL
61 5378 35 M Oral thrush IV 143 Oral swab C.albicans S S S S S S
62 16147 70 M Diarrhea IV 180 Stool NIL
63 7722 44 F Chest pain, loss of appetite IV 124 Sputum NIL
64 11223 34 F Hemoptysis IV 228 Sputum Mycobacteria S
65 6022 54 M Fever, cough IV 33 Sputum Mycobacteria S
66 3317 47 M Cough with expectoration IV 146 Sputum Mycobacteria
67 613 36 M Fever, breathlessness IV 156 Pleural Fluid NIL
68 13102 30 M Breathlessness, cough II 727 Sputum NIL
69 10563 36 M Fever, cough III 185 Sputum NIL
70 13123 27 F Fever, cough with expectoration IV 46 Sputum Mycobacteria S
71 833 54 M Easy fatigue, fever, breathlessness III 321 Sputum NIL
72 117196 44 M Cough with expectoration III 94 Sputum Mycobacteria S
73 38700 40 F
Breathlessness, cough with 
expectoration
III 81 Sputum Mycobacteria
74 55560 43 M Fever, cough with expectoration II 623 Sputum Mycobacteria
75 45321 55 M Headache, neck stiffness IV 32 CSF
Cryptococcus 
neoformans
76 69432 28 M Oral thrush III 65 Oral swab NIL
77 43786 51 F Fever, cough III 420 Sputum NIL
78 47734 24 F Cough with expectoration IV 124 Sputum Mycobacteria
79 46655 32 M Acute diarrhea IV 134 Stool NIL
80 30449 42 M Chest pain, breathlessness II 643 Sputum NIL
81 48296 53 M Oral thrush IV 128 Oral swab C.albicans S S S S S S
82 47812 44 F Oral thrush IV 52 Oral swab C.krusei S S R S S S
83 59883 32 M fever,myalgia,cough III 256 Sputum NIL
84 50037 41 M fever, easy fatigue III 154 Blood NIL
85 45821 53 M fever,loss of appetite IV 223 Blood NIL
86 59344 35 F Acute diarrhea IV 54 Stool NIL
87 48936 43 F Oral thrush IV 64 Oral swab C.tropicalis S S S S S S
88 52085 34 M fever,altered sensorium III 143 CSF NIL
89 52093 46 M fever III 526 Blood NIL
90 58287 40 M Cough with expectoration IV 114 Sputum NIL
91 59464 48 M Cold abscess, loss of weight III 476
Lymph node 
aspirate
NIL
92 57634 36 M Fever, cough III 231 Sputum NIL
93 50954 25 F Oral thrush IV 134 Oral swab NIL
94 64785 39 M Oral thrush III 154 Oral swab C.albicans S S S S S R
95 65687 33 M Loss of weight, Lymphadenopathy IV 32
Lymph node 
aspirate
NIL
96 54678 41 F Cough with expectoration III 119 Sputum Mycobacteria
97 67435 47 F Fever, breathlessness IV 235 Sputum NIL
98 68975 38 M Fever, loss of weight IV 227 Blood NIL
99 62484 22 M Chronic diarrhea IV 162 Stool NIL
S.No IP. No AGE SEX CLINICAL PRESENTATION
WHO 
STAGE
CD4 
COUNT
SAMPLE ORGANISM RIF AK OF CIP COTRI CTX CAZ PT TET IMP AMP B NYS FLU
CLO 
TRI
KETA ITRA
100 78425 46 M Breathlessness, cough II 546 Sputum NIL
101 74563 31 M Diarrhea IV 176 Stool NIL
102 75683 24 M Oral thrush III 132 Oral Swab C.albicans S S S S S S
103 78645 43 M Fever, seizures IV 356 CSF NIL
104 65274 36 F Cough, hemoptysis IV 49 Sputum Mycobacteria S
105 66843 49 F Fever, lymphadenopathy III 565
Lymph node 
aspirate
NIL
106 74865 32 F Oral thrush IV 176 Oral swab C.albicans S S S S S S
107 72497 36 M Cough with expectoration IV 87 Sputum Mycobacteria S
108 74683 49 M Fever, chest pain III 235 Sputum NIL
109 74795 48 M Fever, cough II 519 Sputum NIL
110 81231 34 M Oral thrush III 132 Oral swab C.dubliniensis S S S S S S
111 87644 27 M Fever, loss of weight II 132 Blood NIL
112 83530 47 M Fever IV 385 Blood NIL
113 86073 38 F Fever, cough III 348 Sputum NIL
114 89579 46 F Fever, cough II 584 Sputum NIL
115 64849 36 M Oral thrush IV 210 Oral swab C.albicans S S S S S S
116 86746 43 M Cough , breathlessness IV 38 Sputum NIL
117 43795 44 M Cough with expectoration IV 234 Sputum NIL
118 54738 37 F Chronic diarrhea II 198 Stool NIL
119 57838 34 M Cough with expectoration IV 176 Sputum K.pneumoniae S S S S S S S
120 57857 35 M Fever, cough III 132 Sputum NIL
121 83526 35 M Diarrhea IV 76 Stool NIL
122 84783 37 M Cough, chest pain IV 75 Sputum Mycobacteria S
123 67583 32 M Oral thrush IV 148 Oral swab C.albicans S S R S R S
124 89647 36 M Acute diarrhea III 658 Stool NIL
125 75953 45 M Oral thrush IV 65 Oral swab C.parapsilosis S S S S S S
126 23536 31 F Fever, cough IV 154 Sputum Mycobacteria
127 45467 45 M Diarrhea IV 78 Stool NIL
128 54367 43 F Diarrhea III 564 Stool NIL
129 75467 37 F Fever, breathlessness IV 452 Sputum NIL
130 26286 29 M Oral thrush IV 196 Oral swab C.albicans S S S S S S
131 67697 43 M Fever IV 123 Blood NIL
132 65478 36 F Chronic diarrhea IV 265 Stool NIL
133 21456 24 F Fever, cough II 243 Sputum NIL
134 76464 34 M Fever, cough II 536 Sputum NIL
135 87497 36 F
Breathlessness, cough with 
expectoration
II 678 Sputum NIL
136 64869 38 M Cough with expectoration IV 413 Sputum NIL
137 75496 27 M Oral thrush IV 122 Oral swab C.albicans S S S S S S
138 76483 45 M Diarrhea IV 84 Stool NIL
139 74686 38 F Cough with expectoration III 143 Sputum Mycobacteria S
140 86486 34 F Oral thrush III 163 Oral swab C.albicans S S S S S S
ANNEXURE-5 
 
LEGENDS OF MASTER CHART 
 
AK - Amikacin 
AMP B  - Amphotericin B 
CAZ - Ceftazidime 
CLOTRI  - Clotrimazole 
COTRI  - Cotrimoxazole 
CTX - Cefotaxime 
FLU - Fluconazole 
IMP - Imipenem 
ITRA - Itraconazole 
KETA - Ketaconazole 
NYS - Nystatin 
OF - Ofloxacin 
PT 
 
R 
- Piperacillin-Tazobactam 
 
- Resistant 
 
RIF 
 
S 
 
- Rifampicin 
 
- Susceptible 
TET - Tetracycline 
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